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foREWORD
Intrauterine devices are the most widely used of all reversible contraceptive methods worldwide. Modern
IUDs, particularly those with large copper surface areas
like the Copper T 380, are among the most effective and
long-acting methods of family planning and are suitable
and acceptable options for many women.

TheCopperT 380IntrauterineDevice:A Summaryof SdentificDatapresents highlights of the clinical performance
of this IUD over eight years, including the latest data on
effectiveness, expulsions, and continuation rates. It incorporates the combined data from the Population Council
and World Health Organization studies that were submitted to the US Food and Drug Administration, as well
as important work by scientists at Family Health International and in several countries.
Clinical studies over many years of the three models
of the Copper T 380-the Copper T 380A, Copper T
380Ag, and Gyne T 380 Slimline-have provided substantial evidence of the safety, effectiveness, convenience, ac-

ceptability, and long-acting quality of this IUD.
This monograph is a collaborative effort of staff from
the Population Council's Center for Biomedical Research,
Programs Division, and Office of Communications.
The publication's introductory section describes the
development of the family of Copper T IUDs by the
Population Council and includes a chronology. Next, a
brief profile of the method, suitable for easy reference
and reproduction, focuses on information of particular
interest to family planning providers. The bulk of the
work presents the preclinical and clinical performance,
including mechanisms of action, effectiveness, outcome
of accidental pregnancy, rates of expulsion and ectopic
pregnancy, side effects, continuation rates, return to fertility, and lactation and IUD use. There is also extensive
discussion of the data on IUD use and pelvic inflammatory disease, and the importance of performing skilled
insertions under aseptic conditions. The work contains
a substantial bibliography and glossary of terms.

Figure 1: Evolution of the Copper T IUD
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CHRONOLOGY: COPPER

T FAMILY OF IUDs

1962

First International Conference on Intrauterine Contraception is convened in New York by
the Population Council.

1963

Christopher Tietze, for the Population Council, initiates a large-scale cooperative statistical
program to evaluate IUDs--the most comprehensive and thorough study of a contraceptive
method made to that date.

1964

Second International Conference on Intrauterine Contraception is held, with more than 400
participants from 38 countries.

1967

Howard J. Tatum of the Population Council develops a plastic IUD in the shape of a T.

1968

Jaime Zipper of Chile, a former Council fellow, reports on contraceptive effects of copper
added to the plastic T.

1970

International Committee for Contraception Research is formed by the Council to identify,
develop, and test new contraceptive leads.

1972

Clinical trials begin for Copper T 380 IUD.

1974

Third International Conference on Intrauterine Contraception is held under Population Council auspices in Cairo, Egypt.

1976

US FDA approves the Copper T 200 IUD for distribution in the United States.

1978

US FDA issues its Second Report on Intrauterine Contraceptive Devices, providing guidelines for clinical management of IUDs.

1980

Copper T 220C is marketed, mainly in Mexico.

1984

Copper T 380A is approved for marketing by the US FDA. Conference on Intrauterine Contraception: Advances in Future Prospects is convened in the US by Program for Applied
Research on Fertility Reduction, Northwestern University.

1985

USAID begins distribution of Copper T 380A to developing countries .

1987

WHO scientific group on the safety of IUDs concludes, "The use of IUDs in both developed
and developing countries should continue to be supported as a reliable and safe method of
reversible fertility regulation." United States Centers for Disease Control issues guidelines
for informed decision-making and use of IUDs.

1988

ParaGard 380/CopperT 380A IUD is marketed in the United States by GynoPharma, Inc.

1989

Duration of effectiveness of the Copper T 380A is extended to six years by the FDA.

1991

Duration of effectiveness of the Copper T 380A is extended to eight years by the FDA.

1992

International Conference, "A New Look at IUDs-Advancing Contraceptive Choices," is convened in New York by the Population Council and publishers of the journal Contraception.
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DEVELOPMENT

OF THE FAMILY OF COPPER

The Population Council played a major role in the development, clinical testing, and statistical evaluation of
modern forms of the intrauterine device, starting with
the First International Conference on Intrauterine Contraception convened in 1962. This conference attracted
48 scientists and clinicians from eleven countries. Two
years later, the Second International Conf erence on Intrau terine Contraception was attended by mor e than 400
scientists and public health officials from 38 countries.
By 1964, the Council had provided 81 grants totaling
nearly US$2 million to support research on the acceptability, effectiveness, safety, and mode of action of IUDs.
Several scientists were instrumental to the development process . The late Christopher Tietze directed the
IUD conferences in the early 1960s. Starting in 1963, the
Council supported Dr. Tietze in conducting a large-scale
Cooperative Statistical Program, the first attempt in the
history of contraceptive development to evaluate new
methods from their inception. Dr. Tietze also adapted
life table methods for evaluation of the use-effectiveness
of contraceptives. Jack Lippes, of Buffalo, New York, in
1961 developed the plastic Lippes Loop (shaped like a
double S) under a research grant from the Population
Council. The device was first marketed in 1962. Dr.
Lippes assigned the public sector rights to the Population Council, enabling the organization to encourage local manufacture of the Loop in a number of developing
countries and to arrange for distribution at low cost in
the United States and to national family planning programs in developing countries. In 1967, Howard J.
Tatum, a scientist at the Population Council's Center for
Biomedical Research, developed a plastic IUD in the
shape of a "T". The next year, Jaime Zipper, a former
Council biomedical fellow working in Chile, reported the
contraceptive action of intrauterine copper. The IUD that
combined these two discoveries was the Copper T 200,
the first of the Copper T family of IUDs.
Since the 1960s, scientists at the Population Council's
Center for Biomedical Research played major roles in
the development of the Copper T intrauterine devices .
They coordinated clinical studies; analyzed, reported,
and published the data; developed the manufacturing
prototypes and set manufacturing standards; prepared
applications and reports for regulatory agencies; interacted with other institutions devoted to biomedical and
contraception research; and obtained financial support
for this work.
In 1970, the Council formed the International Committee for Contraception Research (ICCR), a group of experts in reproductive medicine from several countries

T IUDs
dedicated to the development of improved contraceptive
technologies. With intrauterine contraception among the
Council's priorities, the ICCR tested the effectiveness and
safety of the Copper T 200, a polyethylene T with copper wire wound around the vertical stem to provide 200
square millimeters of copper surface area. The Copper
T 200 received US Food and Drug Administration (FDA)
approval for distribution in 1976. Since then, over 50 million of these devices have been distributed worldwide.
The Council refined the Copper T design to increase
contraceptive duration and effectiveness. Two advanced
models resulted: the Copper T 220C, with copper collars
on each transverse arm and on the vertical stem, and the
Copper T 380, which has copper collars on the arms and
copper wire coiled around the stem-the largest copper
surface area of any marketed IUD. Today, there are three
variations of this device: the Copper T 380A, the basic
device, with 380 square millimeters of copper; the Copper T 380Ag-,identical to the 380A but with a silver-cored
copper wire on the stem; and the 380 Slimline, so-named
because the copper collars are located at the tips of the
horizontal arms of the T, permitting an easier fit in the
inserting tube (see Figure 1 for photos of four IUD models). Since 1984, when the Copper T 380A IUD received
US FDA approval for marketing, it has been widely distributed by the US Agency for International Development
(USAID), the United Nations Population Fund (UNFPA),
and other donors to family planning programs in developing countries. Finishing Enterprises of Tonawanda,
New York, has been the major supplier for USAID international public sector programs since the early 1970s. As
of January 1992, over 25 million Copper T 380A IUDs
have been distributed by manufacturers through commercial channels and international public sector distribution programs.

The Council's introduction activities
The Council's Programs Division has focussed on introducing the Copper T380A IUD into family planning programs in developing countries, emphasizing the skills
and information required to provide an advanced model
of an established contraceptive method. The Council has
worked with other international organizations, governments, and country health and family planning officials
to encourage guidelines for safe provision of copper
IUDs. The objective is to serve women better by establishing standards for client selection, service provision,
and improved counseling. Training of service providvii

ers repr esents the chief vehicle for achieving these goals.
Emphasis is on selection of appropri ate IUD u sers; maintenance of aseptic conditions; retraining of providers
accustomed to inserting the Lippes Loop; sensitive counseling of women to help them make the best contr aceptive choices; and dissemination of inform a tion for users
about how the IUD works, how it is inserted and removed, and advantages, possible side effects, and complications. Much of the introduction activity has been
support ed by the US Agency for Internati 0nal Development and the United N ations Population Fund.

IUD use in the world today
The IUD is the most popular reversible method worldwide, used by some 90 million women. In China, which
manufactures a variety of steel rings and copper IUDs,
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over 65 million women use them. The method is also
popular in Scandinavia, used there by from 20 percent
to 40 percent of contraceptors, and by large numbers of
women in Egypt, Germany, Hungary, Indonesia, Mexico,
Taiwan, Tunisia, Turkey, and Vietnam (Mauldin and
Segal, forthcoming). At one time, more than two million wom en in the Unit ed States used IUDs each year ;
this numb er declin ed following probl ems and liability
concerns surrounding the Dalkon Shield in the 1970s. No
copper or nonmedicated IUDs were distributed in the
US for the two years before the Copper T 380A was introduced in 1988, although the Progestasert progesterone-releasing IUD has been available since 1976.

PROFILE:

COPPER

THE COPPER

T 380 INTRAUTERINE

T 380 IUD AT A GLANCE

. EFFECTIVENESS: The Copper T 380 IUD is among
the most effective methods available, with fewer than
one pregnancy per 100 women during the first year
and during each subsequent year.
. LONG-ACTING: The Copper T 380A IUD maybe
used for up to 8 years.
. SHELF LIFE: The shelf life of the Copper T 380A is
four years.
. CONVENIENCE: An IUD does not require daily
attention from the user and does not interfere with
sexual activity.
. NONHORMONAL: Because it contains no hormones, the Copper T 380 IUD does not affect lactation. The copper IUD also avoids side effects common to hormonal methocis.
. LOW COST: Its low initial cost and long life make
this IUD one of the least expensive methods available.
, TII\1lNG OF INSERTION: An IUD may be inserted
at any time during the menstrual cycle, provided the
woman is not pregnant.
. REVERSIBILITY: Contraceptive protection is reversed when the IUD is removed.
• REINSERTION: If a woman has used her Copper
T 380 IUD successfully for eight years and wishes to
continue, a new IUD can be inserted immediately after the old device is removed.

Introduction
The Copper T 380 IUD is one of the most effective, longacting reversible contraceptives available. It has more
copper surface-380 square millimeters-than any other
marketed IUD and is the most advanced of the family of
T-shaped copper devices developed by the Population
Council. The Copper T 380 is inserted high in the uterus,
providing enhanced contraceptive protection for up to
eight years.
More than 25 million have been distributed in over
70 countries. The US Food and Drug Administration approved marketing the Copper T 380A in the United States
in 1984; the IUD was introduced into the US in 1988.

Copper T 380 models
There are three versions of the Copper T 380, which are
known under different brand names in countries where
they are manufactured and/or distributed. The original

DEVICE
product developed by the Population Council is the Copper T 380A.
The Copper T 380Ag, identical to the T 380A except
that its copper wire has a silver core, was developed in
Finland and is approved in that country and distributed
by Leiras Oy, a Finnish company. The Gyne T* 380
Slimline, developed by Ortho Pharmaceutical (Canada)
Ltd., is approved in Canada and the United Kingdom.
The Slimline is so called because its design permits the
horizontal arms to fit more easily into the inserter tube.
Many of the findings in this Profile apply to or derive
from all three models.
Currently, no international criteria exist for regulatory evaluation of IUD devices or manufacturers. Individual manufacturers are subject to the rules of the regulatory authorities in their country. The Council has
maintained close collaboration with manufacturers of
the Copper T to ensure that the product they manufacture is of a standardized quality.
Manufacturers of one or more versions of the Copper T 380 are based in Canada, Finland, and the United
States; producers for local use are located in China, Indonesia, and Mexico .

Components
The Copper T 380A IUD consists of a flexible polyethylene T-shaped body with a copper collar of approximately
66.5 mg of copper on each of its transverse arms and 176
mg of copper wire coiled around its vertical shaft. A
monofilament polyethylene thread is tied through the
bulb at the tip of the T, resulting in two threads to aid in
detection and removal of the device .
The silver core in the copper wire wound around the
stem of the Copp er T 380Ag slows the rate of wire fragmentation. The Slimline differs from the others in that
the copper sleeves are placed at the recessed ends of the
arms and have the same diameter as the plastic .

Research and testing
The Copper T 380 IUD has been rigorously studied both
before and after marketing. Clinical trials of the Copper
T 380A began in the United States in 1972, sponsored and
coordinated by the Population Council's International
Committee for Contraception Research. The Copper T
380 in its three models has been studied in more than 9,500
women in randomized international and national clinical
trials, conducted by the Population Council, the World
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Health Organization, Family Health International, and by
investigators in Brazil, China, India, and Indonesia.

Mechanisms of action
Various hypotheses have been advanced over the years
about mechanisms of action of IUDs, including interference with sperm transport, ovum transport or development, fertilization, and implantation. Until about 1980,
it was believed that the IUD worked mainly by causing
an inflammatory response to a foreign body in the uterus,
thereby interfering with implantation of a fertilized egg
in the uterine wall. The consensus of informed opinion
now has changed.
Studies support the conclusion that Copper IUDs
prevent fertilization by reducing the number and viability of sperm reaching the egg, and by impeding the number and movement of eggs into the uterus. It is believed
that the continuous release of copper from the coils and
sleeves of the Copper T 380 into the uterine cavity enhances the contraceptive effect of the IUD.

Shelf life
The shelf life of the Copper T 380A IUD is four years. If
the date on the individual IUD sterilized packaging has
expired, discard the device and its inserter.

Potential users of a Copper T IUD
The Copper T 380 IUD is a safe, effective, and appropriate method for a woman who:
• wishes a long-term reversible contraceptive that
does not require daily pill-taking or special action
prior to intercourse;
• cannot use or wishes not to use a hormonal method;
• is in a stable and mutually faithful relationship that
does not place her at elevated risk of contracting a
sexually transmitted disease;
• has no history of pelvic inflammatory disease (PIO),
an infection of the upper genital tract; and
• is breastfeeding.

Effectiveness
The annual pregnancy rate of the Copper T 380 is well below one per 100 users, within the range of implantable and
injectable contraceptives and surgical sterilization. In actual
use during the first year, the Copper T 380 IUD is more
effective than most other IUDs, oral contraceptives,
condoms, barrier methods, and periodic abstinence. The
data contained in the US FDA labeling show cumulative
pregnancy rates at three, five, and eight years of 1.5, 1.9,
and 2.3 per 100 users respectively. The effectiveness of the
Copper T 380A IUD was found to be related to age, with
pregnancy rates decreasing for older women.

Duration of effectiveness
The US Food and Drug Administration first approved
the Copper T 380A in 1984 for a duration of four years.
In 1989, based on data submitted by the Population
Council from its and WHO studies, the FDA approved
the Copper T 380A as a contraceptive device effective
for six years. On the basis of further data, in 1991 the US
FDA approved use of the Copper T 380A for eight years.
The eight-year duration applies to the Copper T 380A
IUD governed by US FDA labeling. Approvals by regulatory agencies in other countries may apply to different
models and for different durations of effectiveness.
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While a woman who has no children can use the
Copper T 380, this method should not be a first choice.
Women who have had no children generally have higher
expulsion rates and more bleeding and pain than do
other IUD users.

Who should not use a Copper T IUD
The Copper T 380 IUD should not be inserted in a woman
who:
• is pregnant or is suspected to be pregnant;
• still retains a previously inserted IUD;
• has a known or suspected malignancy of the genital tract, including undiagnosed vaginal bleeding,
or a severe uterine abnormality.
Many of the contraindications to IUD use have to do
with infections. An IUD is not an appropriate
method for a woman who:
• has a sexually transmitted disease (STD) including
a lower genital tract infection, such as gonorrhea
or chlamydia;
• is at a high risk for STDs because she or her partner has multiple sexual partners;
• has active or recurrent pelvic inflammatory disease.

If a woman cannot predict reliably whether she or
her partner will be in a monogamous relationship, it
would be prudent for her to adopt another contraceptive. A woman at risk for a sexually transmitted disease
may also be at risk for transmission of the HIV virus; she
should have her partner use a condom, since an IUD does
not protect against AIDS.

Other considerations
The Copper T 380 IUD should not be the method of first
choice for a woman who has:
• painful or long menstrual periods;
• severe anemia;
• cervical stenosis or narrowing of the cervical canal;
• a recent postpartum or postabortion infection;
• an unresolved abnormal pap smear;

tive. Following good clinical practice and using aseptic
techniques in insertion and removal are critical to avoidance of infection.
Before insertion, the clinician will perform a pelvic
examination to determine the size, shape, depth, and position of the uterus. The Copper T 380A should remain in its
sterile packaging until insertion; the packaging has been
specially designed so the device can be loaded inside the
sterile wrapping. The IUD should be loaded into the inserter tube no more than five minutes before insertion.
The provider guides the Copper T 380 through the
vagina and the cervix to place it at the fundus or top of
the uterus. As the Copper Tis inserted, the arms of the T
will unfold. The woman may feel some pain or cramping at this time. After the inserter is removed, the threads
attached to the end of the Copper Twill be clipped. The
threads will extend into the vagina from the cervical
opening. The Copper T must be removed by a trained
healthcare provider. This can be done easily and safely
in the clinic and only takes a few minutes.

• no access to a health center for follow-up care;
• a condition associated with increased susceptibility to infection, such as leukemia, AIDS, and those
requiring chronic corticosteroid therapy;
• a history of ectopic pregnancy.
A woman with one or more of these conditions who
uses an IUD should be carefully counseled and be examined regularly for potential problems.

Insertion and removal
Insertion and removal of the Copper T 380 IUD are easily
performed by trained physicians, nurse-midwives, and
other paramedics, but providers must become thoroughly
familiar with the procedures before attempting them. Since
the withdrawal technique for inserting a Copper T 380 IUD
differs from the push-in technique used for some other
IUDs, providers must
have appropriate training. Strict adherence to
aseptic practices is vital
to inhibit introduction
of bacteria into the
uterus. Some clinicians
administer antibiotics
just before insertion, although research has
not demonstrated that
this practice is effec-

The importance of counseling
Adequate counseling is important in the selection of
any family planning method; it is essential for informed,
appropriate use. All
women should be offered a choice of contraceptive methods
and be informed of
the advantages and
disadvantages
of
each. Brochures developed for potential
users in different settings are useful in providing information, particularly
when clients are semi-literate. Prototype brochures utilize drawings and easily understood language.
A complete medical and sexual history should be
taken to determine conditions that might influence the
selection of an IUD and to make sure the woman is not
pregnant. A physical examination should include a pelvic examination and Pap smear.
The healthcare provider should give the woman information about:
• who can use and should not use an IUD;
• comparison of IUDs to other methods;
• safety and effectiveness of the Copper T 380;
• how copper IUDs work;
• insertion and removal process;
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• how to check for the IUD string and what to do if
it cannot be felt;
• identification and management of minor side effects;
• importance of using a condom and/or spermicide
in addition to the IUD if at risk of STDs;
• signs of potential complications, including pregnancy;
• where to seek help should problems occur;
• reasons for removal;
• a schedule for routine check-ups and reminder card
for date of removal;
Assure clients they are welcome to return to the
health facility if they are concerned about any aspect of
IUD use.

Timing of insertion
The Copper T 380 IUD may be inserted at any time during the menstrual cycle, provided the woman is not pregnant and has been consistently using an effective contraceptive since her last menses. Many clinicians prefer
to insert an IUD within seven days of the onset of menstruation because the cervical opening is slightly dilated
during this time, making insertion easier and pregnancy
very unlikely. Insertion during these days also is likely
to result in less discomfort, cramping, and/ or spotting
for the patient.
With special training and careful technique, a clinician can insert a Copper T 380 postpartum within minutes after expulsion of the placenta. Expulsion rates tend
to be at least two times higher when an IUD is inserted
immediately postpartum than those found during interval insertion. In addition, clinicians need to ensure that appropriate client counseling and screening have taken place
before the birth. Many clinicians prefer to insert an IUD six
weeks or later postpartum, when the woman returns for a
checkup. Special care should be taken when inserting an
IUD in a lactating woman because of the possible increased
risk of uterine perforation during lactation.
The Copper T 380 IUD may be inserted immediately
after an uncomplicated first trimester miscarriage or an
induced abortion. A provider must ensure that time is
available for counseling and appropriate STD screening.

Use during lactation

feeding women using the Copper T 380 as compared to
their nonbreastfeeding counterparts. Breastfeeding
women had fewer problems with bleeding and pain following IUD insertion; they had higher continuation rates
than women who were not breastfeeding in the six
months following insertion.

Reasons for removal
The Copper T 380 should be removed whenever the
woman wishes, for whatever reason, and at the end of
eight years. In addition, these conditions are cause for
removal or concern:
• pregnancy;
• unexplained, severe, or prolonged vaginal bleeding or discharge;
• severe pelvic or lower abdominal pain or cramps;
• unexplained fever with pelvic tenderness;
• disappearance of the IUD's strings; or
• continued pain during sex.

If the IUD is removed and the woman does not wish
to become pregnant, she should be provided with an alternative contraceptive.

Side effects and complications
Most women have some bleeding following insertion of an IUD, and menstrual cramps may
develop or worsen. Cramping is more severe in the first
few months after insertion and usually diminishes over
time. Menstrual bleeding may be heavier and longer than
usual, and bleeding between menstrual periods can occur during the first two or three months after insertion.
As with cramping, heavier bleeding generally decreases
over time.Pain and bleeding are the most common side effects
reported by users of copper IUDs and are the most frequent reasons given for discontinuation in the first year
or two of use. Randomized comparisons with other IUDs
have shown little difference in removal rates for bleeding and/ or pain among parous users. Copper IUD use
may induce iron deficiency in some women; programs
should be prepared to treat iron deficiency then or before a woman is given an IUD.
PAIN AND BLEEDING:

Spontaneous expulsion of a Copper T 380 IUD
is more likely to occur during the first three menstrual
cycles following insertion than during any other time.
Expulsion rates are affected by the training and technical skill of the provider; the age of the IUD user and
EXPULSION:

The Copper T 380 IUD may be used by breastfeeding
women. Studies have shown no adverse effect on quantity or composition of breastmilk. Multicenter clinical trials found no increased risk of adverse effects for breast-
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whether or not she h as ever had any childr en; and the
timing of the insertion.
N ulliparous wom en and those with IUDs inserted
imm ed ia tely after expulsion of the placenta are more
likely to expel an IUD than are other women. The IUD
user should check the strings of the devic e after each
menstrual period, to make sure the device has not been
expelled.
Perforation of the uterine fundus
is a rare complication of IUD insertion. This risk is lessened by careful insertion. An IUD in the abdominal cavity must be removed surgically. There is som e evidence
that the risk of perforation is greater early postpartum,
before the uterus is fully involuted. Special care is required when the Copper T 380 is being inserted at this
time, whether or not the woman is breastfeeding.
UTERINE PERFORATION:

IUD IN PLACE: Pregnancy with the Copper T 380A in place occurs at rates of less than one per
100 women per year. If a woman using an IUD becomes
pregnant the IUD should be removed. The task is easily
accomplished if the string is visible, and removal is routine.
If the IUD is left in place with the strings not visible,
the woman runs a risk of an early spontaneous abortion
or a later septic abortion, with possible life-threatening
consequences, or premature labor. As a consequence of
premature birth, the infant may be at increased risk. The
woman should be counseled about the risks of continuing her pregnancy, and termination of the pregnancy
may be considered and offered as an option.
PREGNANCY WITH

ECTOPIC PREGNANCY: Ectopic pregnancy is an infrequent,
but dangerous, type of pregnancy that develops outside
the uterus. In about 4 percent of pregnancies with an IUD
in place, the pregnancy is ectopic. Women with an increased risk of ectopic pregnancy are those who:

• have a history of ectopic pregnancy; or
• have ever had a pelvic inflammatory disease or
sexually transmitted disease.
If a woman older than 35 becomes pregnant, she is
more likely to experience an ectopic pregnancy than is a
younger pregnant woman.
Because the Copper T 380 IUD is very effective, users of this device have a low risk of ectopic pregnancy,
substantially lower than women not using contraception.
If a pregnancy occurs with the Copper T 380 in place,
however, it is more likely to be ectopic than a pregnancy
after the failure of a barrier method or the combined pill.
A pregnancy with the Copper T 380 is less likely to be
ectopic than a pregnancy after failure of steroid-releasing IUDs, NORPLANT®, the minipill, o.r sterilization.

(PID): IUDs do not protect
against PIO infections, which are caused by gonorrhea,
chlamydia, or other microscopic organisms. When PIO
occurs, it may be serious. PID can necessitate a hysterectomy and can damage the fallopian tubes, leading to ectopic pregnancy or infertility, or, rarely, death.
IUD use has been associated with increased risk of
PIO in the first one to four months of use. The risk is
highest just after insertion when bacteria may be introduced into the uterus by the insertion process.
Exposure to sexually transmitted diseases also increases the risk of PIO. Women who have multiple sexual
partners, or whose partners have multiple partners, run
a greater risk of contracting PIO. The risk of PIO decreases with long term IUD use.
PELVIC INFLAMMATORY DISEASE

Tarnishing of copper
Copper-bearing IUDs may show discoloration in their
sterile packaging, but this should not cause alarm . The
copper tarnishes because air passes through the sterile
IUD package, causing an oxide or sulphide film to form
on the surface. IUD packaging has to be permeable to
gases used to sterilize the devices. If the package is not
damaged, and the expiration date on the package has not
passed, the IUD will be sterile even if the copper on the
device is tarnished. Laboratory studies show the tarnishing does not affect the safety or effectiveness of the IUD.
However, several steps have been taken in the manufacturing process to diminish the tarnishing.

Continuation rates
Continuation rates of IUDs have been among the highest of all reversible contraceptives. In combined data from
the Population Council and World Health Organization
studies, 77 percent of women continued using the Copper T 380A for one year. Sixty percent of the women continued for two years, and almost half for three years, with
29 percent continuing for eight years.

Prevalence of use
Worldwide, the IUD is the most widely used reversible
contraceptive. IUD use varies from country to country,
reflecting differences in culture, availability, and choice
of contraceptives, attitudes and training of providers, and
fertility goals of women. In Scandinavia, 20 percent to
40 percent of contraceptive users have IUDs, while about
60 million Chinese women use IUDs. A recent US sur-
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vey showed that women who , were using IUDs were
more satisfied with the method than were women using
other contraceptives.

Return to fertility
The contraceptive effect offered by the Copper T 380 IUD
is reversed when the device is removed. Conception rates
following removal for planned pregnancy are normal,
with rates of successful planned pregnancy unaffected
by duration of IUD use.
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Postmarketing studies
In addition to numerous clinical studies, the Copper T
380 IUD is one of the devices being studied as part of a
long-term postmarketing surveillance comparing health
effects of NORPLANT® implants with IUDs and sterilization. The study, conducted by the World Health Organization, the Population Council, and Family Health
International, compares 8,000 users of NORPLANT®
with 1,500 sterilized women and 6,500 users of various
IUDs, including the Copper T 380, over five years.

flIGHLIGHTS

OF PRECLINICAL AND CLINICAL PERFORMANCE

Active ingredient-Copper.

Effectiveness- Cumulati ve pr egnan cy rates, US Food
nd Drug Adm inistration labeling: First year: 0.6 preg~ancies per 100 users; three year s: 1.5; five years : 1.9; eight
years: 2.3.
ouration-Approved
for eight years of use by the US
Food and Drug Administration.
Mechanism of action-Copper ions dissolving into the
uterine cavity from the IUD's copper collars and wire
greatly enhance cytotoxic and phagoc ytic effects initiated
in reaction to the plastic IUD platform. Copp er IUDs inhibit sperm and ovum transport and/or the capacity of
sperm to fertilize ova .
Side effects-Increased menstrual bleeding and pelvic
pain; mode rately increased risk of pelvic inflammatory
disease; mod erat e decrease of hemoglobin during the initial two years.
Reversibility-Immediate

upon removal.

Components

Preclinical Evaluation

The Copper T 380 IUD (see Figure 2) has a T-shaped polyethylene frame with 380 square mm of surface area of
copper - the most found on any commercially available
copper IUD. Approximately 176 mg of copper wire is
wound around its vertical stem, with 66.5 mg copper collars on each of its transverse arms. The device is 36 mm
long and 32 mm wide, with the tip of the vertical arm
enlarged to form a bulb 3 mm in diameter. A polyethylene monofilament is tied through the bulb, resulting in
Figure 2: Copper T 380 IUD
horizontal arm (32 mm)-"7
polyolh ylono T lrame
66.5 mg copper ootlar

I

=

I

66 .S mg copper collar
176 mg copper wire
(silver wire core
in Ag model)

vertical stem (36mm)-

bulb (3mm)

two threads that aid in detection and removal. As long
as the device retains significant amounts of copper, it is
radiopaque. Barium sulfate added to the plastic frame
contributes to radiopacity.
The Copper T 380A model is packaged together with
an insertion tube and a plunger in a pouch and then sterilized, either by ethylene oxide gas or by radiation. The
insertion tube is equipped with a movable flange to aid
in gauging the depth to which it is inserted through the
cervical canal and into the uterine cavity. The shelf life
of the Copper T 380A is four years.
The Copper T 380Ag was developed to increase the
effective lifespan of the IUD. In this variant, the copper
wire contains a silver (Ag) core to maintain the integrity
of the wire for per iods of eight or more years. This version of the Copper T 380 was develop ed by Outokumpu
Oy, and is now marketed by Leiras Oy, of Finland.
The Gyne T* Slimline was developed by Ortho Pharmaceutical (Canada) Ltd. to enhance insertion by permitting the arms with collars to fit more easily into the insertion tube.

--

=

'f

polyethylene
monofilament strings

Toxicology and pathology

Copper ions are highly toxic to single-celled organisms,
but mammals have effective buffering systems to cope
with intakes far above their daily nutritional copper requirements .
Several studies have been directed to the effects on
organs and tissues of animals exposed to copper in utero
and intra-abdominally. Experiments in which copper was
placed in the uterus and abdominal cavity of rats (MooYoung, 1972) and monkeys (Moo-Young et al., 1973)have
shown no important increments in copper contents of tissues. In a study conducted for the Population Council
and Searle Laboratories, organs of monkeys exposed to
copper in uterocontinuously for six to seven years were
analyzed for copper content. The only significant increment as compared with control animals was in the uterus.
In one-year studies in monkeys, the only significant
evidence of adverse effects was found in animals in
which the devices were placed intra-abdominally. Marginal evidence of irritation in the vicinity of the devices
was noted four years after placement in utero.A sevenyear study of monkeys showed the duration of menstrual
bleeding was increased by copper devices placed in utero.
Some devices placed in the abdominal cavity penetrated
pelvic organs and caused mild to severe lesions. More
•Trademark GyneT380, Ortho Canada
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endometriosis and adhesions were observed in IUD
groups than in controls with no devices. No neoplastic
changes attributable to the devices were observed.
Because copper wire may fragment after prolonged
uterine use, the fate of copper fragments introduced into
the uteri of monkeys was examined. Fragments were generally expelled, although recovery was not quantifiable.
X-rays did not show that they had lodged in tissue. In
one experiment, 100 mg of small copper fragments were
placed in the uteri of monkeys a few days before menstruation and were studied after the first or second subsequent menstruation. Copper concentrations in the liver
and lungs were not elevated above control levels.
Teratological studies have been conducted in rats, hamsters, and rabbits. Copper was introduced in the uterus after conception (Chang and Tatum, 1973).In initial studies,
the only effects were in the reduction of the number of offspring delivered in rats and rabbits. Additional studies gave
evidence of some fetotoxic effects, but no evidence of teratogenic effects. Other investigations found no evidence of
teratogenic effects in mice. To date, human studies give no
evidence of teratogenic effects or elevated rates of birth defects (Atrash et al. , forthcoming).

Mechanisms of Action
Effect on sperm and ova

Various hypotheses have been advanced for mechanisms
of action of IUDs, including interference with sperm
transp ort, ovum development, fertilization, and imp lantation. Until about 1980, it was thought that an IUD acted
by preventing a fertilized egg from implanting in the
uterus. The consensus of informed opinion has changed,
howev er; it is now believed that copper IUDs greatly reduce the likelihood of fertilization. Recent data and analysis (WHO, 1987; Ortiz and Croxatto, 1987; Sivin, 1989b)
indicate tha t the main antifertility effects of copper-bearing lUDs involve inhibition of egg or sperm transport
and/ or the capacity of sperm to fertilize eggs, thro ugh
cyto toxic and phagocytic effects. Reduced gamete trans port and capacitatio.n inhibits fertilization and occurs before the ovum reaches the uterine cavity.
Figure 3 describes the mechanisms of contrac eptive
action of an IUD placed high in the uterine cavity and
continuously releasing copper.
Continuous copper release into the uterine cavity
from the wire and sleeves enhances the contraceptive effectiveness of the Copper T 380. In one study of women
about to undergo sterilization, sperm were re cove red
from the fallopian tubes of women using no contraception 15 to 30 minutes after insemination, but no sperm

L:__

Figure 3: Mechanisms of Contraceptive Action of
Copper IUDs

Inhibition of sperm transport

Copper enhances the contraceptive effectiveness of IUDs. Few sperm
reach the fallopian tubes and their capacity to fertilize eggs is reduced ;
fewer eggs are found in the tubes ot women using copper IUDs. The
principal action of IUDs occurs before an egg reaches the uterus . There
is a marked reduction in the probability of fertilization .

were found in the tubes of IUD users at the same postcoital time (Ortiz and Croxatto, 1987).
Table 1 shows the lack of sperm and diminished
numbers of ova in fallopian tubes of women undergoing sterilization. In two studies, spermatozoa were recovered from the upper reproductive tracts of noncontracepting women around 12 hours after sexual
intercourse, but greatly reduced numbers were recovered
from users of inert, non-copper IUDs, and none were
found in the tubes of copper IUD users (Aref et al., 1983;
Tredway et al., 1975). These differences were statistically
significant. In another study of women about to undergo
sterilization, investigators searched for ova in the fallopian tubes and uteri of non-contraceptors and of women
using Copper T IUDs (Alvarez et al., 1988). Ova were
found in the fallopian tubes of 56 percent of women using no contraception and 30 percent of Copper T IUD
users (p<.05). No ova were recovered from the body of
the uterus of any of the IUD users, indicating a contraceptive effect of the IUD before the ovum reaches the
uterus . Of women from whom tubal ova were recovered,
20 nonusers of contraception and five Copper T IUD users had sexual intercourse dµring their fertile days. Microscopic features indicating normal preimplantation
development of fertilized eggs were observed in half of
the 20 ova of the non-contraceptors and in none of the
eggs of the five copper IUD users who had intercourse.
Thus, the likelihood of ova being fertilized en route to

,
Table 1 Presence of spermatozoa and ova in fallopian tubes of women undergoing
sterilization
Presenceof sperm 12 hours after coitus

Firstauthor

Contraceptive

Tredway

None
IUD

Arel

None
Nonmedicated IUD
Copper IUD

Specimenswith
sperm present

(N)

Percent
with sperm

6
0

(6)
(4)

o·

11
0

(15)
(10)
(10)

73
40
0..

Women with
1+ ova present

(N)

64
8

(115)
(27)

4

100

Presenceof ova 37-132 hours after LH peak

•

Firstauthor

Contraceptive

Alvarez

None
Copper T 200 IUD

Percent
with ova
56
30*

•The difference between these rates is statistically significant at p<.05 .
.. The difference between these rates is statistically significant at p<.001.

the uterine cavity containing a copper-bearing IUD is
much reduced.
Further evidence that the IUD acts by inhibiting fertilization is the absence or only rare presence of chorionic gonadotropin, a substance produced by developing
embryos beginning at the blastocyst stage, in the blood
of women using copper IUDs. Segal and colleagues
(1985) took blood samples from three groups of normally
menstruating young women: 30 Copper T 200 IUD users, 30 sterilized women, and 15 who were trying to become pregnant. The only women who tested positively
for human chorionic gonadotropin (hCG) were attempting pregnancy; they were later found to be pregnant. In
a larger study, Wilcox et al. (1985) employed highly sensitive and specific immunoradiometric assays to demonstrate that hCG rises were rare among IUD users as compared with controls.
Epidemiological studies of ectopic pregnancy shed
light on how IUDs work. If the IUD were an abortifacient,
preventing uterine implantation of fertilized eggs, ectopic
pregnancy rates among IUD users would be at least as
high as among women who did not use contraception.
This is because ectopic pregnancies develop before the
fertilized egg reaches the uterus. On the other hand, if
IUDs tended to prevent fertilization, fewer ectopic pregnancies would be found than in women using no contraception . Both the Women's Health Study (1981) and
the WHO case-control study of ectopic pregnancy (1985)
found the risk of ectopic pregnancy among IUD users to
be about one-half that of women who used no contraception. The risk of ectopic pregnancy among wom en
with IUDs is directly correlated with the effectiveness of
copper IUDs; the lower the accidental pregnancy rate,
the lower the rate of ectopic pregnancy (Sivin 1991b).
Since ectopic pregnancies develop before the egg can

reach the uterus, these findings of significantly reduced
rates of extrauterine pregnancy imply that IUDs act before the egg reaches the uterus, presumably by inhibiting fertilization.
The exact mechanisms by which sperm transport
and/ or fertilizing capacity are decreased in copper-bearing IUD users have not been fully elucidated. All types
of IUDs increase the number of uterine leukocytes and

TARNISHING OF COPPER

The wire and sleeves of all types of copper-bearing IUDs occasienally discolor or darken within the
11>ackage.
This occurs because air can pass into the
IUD package, causing a thin film of copper oxides
or sulfides to form. Surface oxidation can produce a
variety of colors depending on the thickness of the
films that form (Evans, 1960). IUD packaging must
be permeable to ethylene oxide gas used to sterilize
devices. Laboratory studies as well as clinical experience show that these tarnished or darkened IUDs
are safe and remain as effective as brighter Copper
T 380s (Tsang and Nash, 1991).
For copper ions to be released from the metallic
c0p~ of the IUD i'nto the uterine cavity, oxidation
must occur. Tsang ~mdNash (1991)show tnat in the
presence of serum whose compesitien dose)y resembles that of uterine fluids, tarnish is quickly dissolved. No differences can be detected in copper release from initially tarnished or from bright
untarnished copper. Tarnish does not diminish the
availability of copper ions in utero.In fact, dissolution of copper from the wire or sleeves proceeds
through the same oxidative processes (Oster, 1972;
Kosonen, 1980).
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the amount of degradation products. Sperm may be destroyed through phagocytosis and through cytotoxic effects of copper or by cell degradation products. Copper
is spermicidal and cytotoxic (Holland and White, 1988).
Sperm incubated in media previously exposed to copper IUDs maintained normal motility, but exhibited reduced capacity to penetrate bovine cervical mucus
(Shoham et al., 1987).

Clinical Pharmacology
Cytology

Data on initial and repeat Papanicolaou smears were
available for 1,767 women in the Population Council
study (Sivin and Stern, 1979). Percentages of women in
class III (dysplasia) and higher ranked smears at insertion (1.3 percent) and at the last test (1.5 percent) were
similar and within normal ranges. These data indicate
that the presence of a copper IUD does not adversely affect the incidence of clinical carcinoma.
Clinical chemistry

Serum chemistry profiles of organ function for 15 women
using the Copper T 380A followed through three years
showed few abnormalities (New Drug Application submission). The most frequent deviations from normal were
low glucose or potassium levels, which were not of physiological importance. In studies of more than 50 women
using the Copper T 220C for at least four years, of 60
women using Copper T 200 for at least five years, and of
126 women using the Copper T 380Ag for three years,
frequencies of abnormal serum chemistry measur ements
were well within expected incidences (NORPLANT®
NOA submission, 1988). Serum copper 1evcls among
Copper T380A users were also within normal limits and
showed no trend over three years.

Clinical Overview
Extent of clinical experience

The initial clinical trials of the Copper T 380A, sponsored
and coordinated by the Population Council, began in 1972
at several investigational sites in the United States. A total
of 3,536 volunteers participated at clinics that maintained
good follow-up. Of the total, 1,679 were in randomized trials with the Copper T 200. More than a thousand women
who started use in 1972 in seven of the centers were followed for up to four years (Sivin and Stern, 1979;Sivin and
Tatum, 1981).These Population Council trials provid ed the
basis for the approval of the Copper T 380A by the US Food
and Dnig Administration in 1984.
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COMPUTING RATES FOR PREGNANCY AND
OTHER EVENTS
PREGNANCY and other event or termination
rates are cakulate<:i in sevetal ways from clinical trials and, SUJTVey
data, usually as lifetaole gross event
rates or lifetable net e,,rent rates, or the Pearl Index.
. Unlike annual pregnancy rates, which tend to de. crease wi'th time, cumulative pregnancy rates must
either increase year by year or remain unehanged.
Cumulative rates cannot decrease.
LIFETABLE or ,mtuarial tecl\niques are used to
take int0 account the varying length& of time that
women remain in studies. Event rates are estimated
0n a aaily or monthlybasis for women continuing to
use a m'eth©d. These rates are then integrated te estimate annual or cumulative event rates. Lifetable rates
are expressed in two ways: gross and net.
GROSS EVENT RATES are estimates of the annual or cumulative probability of an event, such as
pregnancy or expulsion, tha:tis unaffected, in theory,
by the rates at which ebmpeting events occur. The
gross rate is an estimate of the intrinsic rate at which
an avent occurs. Gross rates are most approp,riate for
a0mpairing different deviaes in a ~ingle trial 0:rfor
comparing the performance of the same deviee across
various clinics or populations.
NET EVENT RA 'FESallew for the presenre of
competing ris~ 0f ter,n:unation1 for example, some
women may have expelled or removed the device before they had a chance to become pregnant. Net rates
are most appropriate for estimating the relative importarnre 0f discontinuation for accidental pregnancy,
bl~ing aNd pain, plann<?dpregnancy, expulsion, 0r
medkal reasm~s.
PEARL INDEX is a measure 0finctdenoo'and,represents the number of events, e.g. pregnancies, divicloclby c;,cposwe -the t0tal durafion t,Jfuse by all
won:ien in the stuay. The Ind~ is expressed as the
numeer of pregnanties 61' other events per 1.00
woman-years of use. An ·overall Fearl Index does not
take accountofp0ssibly changing risks of pregpancy
orother events with time. An annual Pearl Index does
this.

Subsequently, several international randomized trials of the Copper T 380 IUD (models A, Ag, and Slimline)
have been conducted by the Population Council, the
World Health Organization, and Family Health International, and single-country randomized trials have been
conducted in Brazil, China, India, and Indonesia. All randomized trials published before 1992 are listed in Table
2, including the 1,679 women who participated in the randomized component of the initial US Population Coun-

Table 2 Randomized clinical trials of the Copper T 380 IUD
(N)"

Years of
follow-up

(1,679)

2

(391)

3

Authors

Sponsor

Country

TCu 380A
Sivin and Stern
Roy et al.

Population Council
Population Council

us
us

Dfaz et al.
Chi et al. b

Population Council

Brazil

(159)

Family Health International

International

(589)

Rowe, Farley et al.
(WHO)

World Health Organization

International

(1,396)

8

Sastrawinata et al.

Indonesian FertilrtyResearch
Program

Indonesia

(946)

2

Sivin et al.

Population Council

International

(298)

2

Family Health International

International

(737)

3

Family Health International

(181)

3

(892)
(892)

3

(1,121)

8

TCu 380Ag
Cole et al.; Champion
et al.
Cole et al.; Apela et al.
Sung et al.; Tianjin
Family Planning

Tianjin Municipal Health Bureau;
Tianjin Family Planning

UK and
Philippines
China
China

Sivin et al.

Population Council

International

Saxena et al. (ICMR)

Indian Council of Medical
Research

India

(434)

3

Population Council

International

(698)

2

Gyne T Slimline
Sivin et al.

3

• Numberrandomizedto CopperT 380 users;approximately
equalnumberusedotherIUDs.
b Foursinglecliniccomparisons,
eachwitha differentcomparative
IUD.

cil trials. A total of 9,521 women who used the Copper T
380 have participated in the randomized trials. Published
experience in these trials exceeds 20,000 years of use.
Long-term randomized trials in excess of eight years of
continuous use are currently being conducted by the
WHO and by the Population Council.

Contraceptive effectiveness
The Copper T 380 is one of the most effective contraceptives in use, with an annual pregnancy rate, on average,
of less than one per 100 users. Figure 4 shows annual
pregnancy rates summarized from randomized trials of
the variants of the Copper T 380 for each of the years
that the devices have been approved.
The annual pregnancy rates observed in each trial,
expressed as Pearl indices, appear in Table 3, as do the
annual pregnancy rates for each variant of the Copper T
380. Each of the three variants-Copper
T 380A, Copper
T 380Ag, and Gyne T Slimline-has average annual pregnancy rates that are well below one per 100 woman-years,
although, by chance, individual studies have been higher.
The highest first-year rate was found in the Population
Council's 1972-1975 US trials, in which '60 percent of the

participants were under age 25 at admission. Accidental
pregnancy rates among IUD users are highest among the
youngest users. This is the case with most other types of
contraception.

Figure 4: Annual Pearl pregnancy rates per 100 womanyears for Copper T 380 models in all randomized studies
0.75

0.6

8

0.45

lil

Copper T 380A

D

Copper T 380Ag

•

All 380 models

....
(l)
a.
(l)

~

0 .3

0.15

0

2

·annual rate

o.o

3

4

5

6

7

8

Year of use
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Table 3 Annual Pearl pregnancy rates per 100 woman-years in randomized trials , Copper T
380 IUD, years 1-3
Pregnancy rates
Authors

Mean/Median age

Year1

Year2

Year3

(N)

TCu380A

Sivinand Stern
Roy et al.
Diaz et al.
Chi et al.
Rowe, Farley et al.(WHO)
Sastrawinata et al.
Sivinetal.

22.6
23.5
26.5

0.0
0.5

28.7
26.0
28.4

1.3
0.6
0.0
1.0
0.3
0.5
0.4

Total TCu 380A

0.4
0.8
1.5

0.3

26.2

0.7

0.5

0.3

(5,458)

Cole et al.; Champion et al.•
Cole et al.; Apelo et al.•
Sung et al.
Sivinetal.
Saxena et al. (ICMR)

26.7
28.7
32.0
26.6
25.9

0.3
0.7
0.1
0.3
0.8

0.3"

o.o•

o.o·
o.o•

0.4
0.5
0.3

0.7
0.2
0.0

(737)
(181)
(892)
(1,121)
(434)

Total TCu 380Ag

26.7

0.3

0.4

0.3

(3,365)

Sivinet al.

27.8

0.3

0.0

All variants

26.6

0.5

0.4

TCu380Ag

{1,679)
(391)
(159)
(589)
(1,396)
(946)
(298)

0.0

Gyne T Slimline
(698)
0.3

(9,521)

Note: Dash(-)= not published or not studied.
• Subset of clinicsin Cole et al., 1985.

In individual randomized trials, the Copper T 380
had significantly lower first-year pregnancy rates than
the Copper T 200 (Sivin and Stern, 1979; Chi et al., 1990),
the Copper T 220C (WHO, 1990), the Lippes Loop D
(Diaz et al., 1982), the Mahua steel double ring used in
China (Sung et al., 1984), and the MLCu 375 (Sastrawinata et al., 1991; Rowe 1992). In other randomized
studies, the Copper T 380 has had lower first-year pregnancy rates than the Multiload MLCu 250 (Chi ct al.,
1990), the Multiload MLCu 375 (Cole et al., 1985; Champion et al., 1988), and the Cu7 (Cole et al., 1985; Apelo et
al., 1989), but the individual compa r ison s we re no t signifi cant (see Tabl e 4). In the 19 compari sons show n in
Table 4, the Copper T 380 had the lower pregnancy rate
in 15 studies . In no comparison has another IUD had a
significantly lower p regnancy rate than that exhibited by
the Copper T 380 at a ny duration of use. The sligh tly differen t ra tes of pregnancy of the Cop per T 380 in the randomized studies reflect chance occurrences, the differing charact eristics of the study groups, and the different
investigators and clinics . The Copper T 380 is more effective than non -medicated and most other copper IUDs
(WH O , 1987; Sivin and Schmidt, 1987).
Th e first-yea r pregn an cy ra te of the Coppe r T 380
IUD is w ithin the range of effec tiveness of impl antable
or injec table hor mona l contr acepti ves and surg ical st erilization. Actual use of IUDs show s them to be more ef-
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Table 4 First-year gross pregnancy rates per 100 women

in randomized comparative trials
First author

TCu 380
rate

Other device
Rate

Name

Nonmedicated IUDs

Sung
Diaz
Sastrawinata
Chi

0.1*
0.4
1.5

3.3
4.1
1.4
1.8

Mahua
Lippes
Lippes
Lippes

1.2*
0.8*
0.8
0.6
0.7
0.3
0.4*
0.5*
0.3*
0.5
0.7
0.1
0.8

3.6
6.2
0.9
3.8
2.1
0.8
1.4
1.2
1.1
1.1
2.2
0.4
0.0

TCu 200
TCu200
TCu 200
Cu?
MLCu250
MLCu375
MLCu375
MLCu375
TCu 220C
TCu 220C
TCu 220C
TCu220C
TCu220C

0.8
0.3

0.0
0.2

LNg20
LNg20

o.o·

Copper IUDs

Sivinand Stern
Chi
Saxena (ICMR)
Cole
Chi
Cole
Sastrawinata
Rowe (WHO)
Rowe, Farley (WHO)
Roy
Chi
Sung
Saxena (ICMR)
Levonorgestrel IUDs

Saxena (ICMR)
Sivin

*Thedifferencebetweenthese rates is statistically
significant
at p<.05.

Figure 5: Probability of experiencing a pregnancy in the first year of contraceptive use, per 100 users
(US) Spermicide
(US) Diaphragm
(S) Rhythm, Periodic Abstinence
(S) Withdrawal
(US) Condom
(S) Pill
(S) IUD
(C) Injectable
(C) Copper T 380 IUD
(C) Female Sterilization
(C) NORPLANT
(C) Vasectomy

-·
-••
I

0

2

4

6

8

10

12
16
14
18
20
First-year probability per 100 users

22

24

26

28

30

32

US=Surveys of Fam ily Growth
S=15 national Demographic and Health Surveys (OHS)
C=Clinical studies

Note : In computing ranges for the survey -derived data, the highest and lowest failure rate reported for each method have been
omitted, i.e .. the range represents an 87 percent interval for each method .

fective in the first year than are oral contraceptives,
condoms, barrier methods, and periodic abstinence, as
judged by national sample surveys of women in 15 countries (Moreno and Goldman, 1991). Long-term (five or
more years) pregnancy rates have been lower than that
observed in studies of NORPLANT® implants (Population Council data, reflected in the US labeling).
A comparison of first-year accidental pregnancy rates
of various methods is shown in Figure 5. The data derive from national surveys of contraceptive failure in 15
developing countries (Moreno and Goldman, 1991) and
the United States (Trussell and Kost, 1987; Trussell et al.,
1990). For some methods, like NORPLANT® implants,
national sample survey data do not yet exist, and clinical trial data have been used.
US FDA approval of continuous use of the Copper
T 380A for eight years (1991) was based on combined
data from two sources: the original trials conducted in
the US by the Population Council representing 3,536
women in randomized and non-randomized trials and
the WHO randomized study involving 1,396 users of the
Copper T 380A in 13 clinics in nine countries. The cumulative gross pregnancy rates for the combined data
are shown in Figure 6.
Cumulative pregnancy rates of the Copper T 380A
in the WHO study at nine years were 2.1 per 100 users
(WHO 1990; Rowe, forthcoming). In an eight-year Population Council study, the cumulative rate at the end of
the period was 1.4 per 100 users of the Copper T 380Ag.

Long-term follow-up in the WHO study of the Copper T 380A and in the Population Council study of the
Copper T 380Ag has continued. Ten-year data have been
submitted to the US FDA for review and possible extension of approved life of the IUDs.
Large randomized trials and cohort studies have
found pregnancy rates of the Copper T 380 and other
IUDs to decrease with age (Tietze and Lewit, 1970;
Vessey, 1982;Sivin and Stern, 1979;Sivin et al., 1990a). Pre-

Figure 6: Cumulative gross pregnancy rates per 100
Copper T 380 users, through 8 years
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sumably this occurs because younger women have a greater
frequency of intercourse. Figure 7 shows two-year cumulative gross pregnancy rates by age for various IUDs. The
two-year cumulative pregnancy rate among women less
than 20 years of age at acceptance was 2.0 per 100, whereas
it was 0.6 per 100 for women aged 25 to 29, and 0.0 for
women aged 30 or older when they started to use .the Copper Tin the initial Council study (Sivin and Stem, 1979).
The very low pregnancy rates among women aged 35 or
older who used copper devices or the Llppes Loops C and
D provide a partial explanation of the low pregnancy rates
observed at 6 to 10 years of Copper T 380 use, even when
the devices are releasing less copper. The very long-term
users tend to be above age 35.

Duration of use
The original 1984 approval of the Copper T 380A was
for four years based exclusively on the Population
Council's US clinical trials. Approval for eight years
(1991) is based on both the US trial data and those of
WHO. The eight-year approval for the Copper T 380A
applies to the labeling approved by the US FDA. Versions of the Copper T manufactured in other countries
may have been approved for different durations and are
subject to the national regulatory requirements of the
concerned countries. Therefore, the Copper T 380A may
not be approved for eight years in each country.
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Outcome of accidental pregnancy
If a pregnancy occurs with an IUD in place, the device
should be removed. Removing the IUD decreases the risk
of an early spontaneous abortion and of later septic abortion with its possible consequence of septicemia, septic
shock, and death. When the IUD string is visible, removal
during pregnancy is easily accomplished, and may improve chances of carrying to term if that is desired. The
WHO recommends that if removal proves difficult or if
the strings are not visible, the woman should be told
about the risks of continuing with the pregnancy (WHO,
1987). Termination of pregnancy may be offered as an
option. If the IUD is not removed, the woman should be
followed more closely than other pregnant women.
Long-term effects on the fetus or child have not been exhaustively documented. Atrash et al. (forthcoming) report that an IUD in situ is not associated with congenital
malformations, even if the device is not removed and the
fetus is carried to term.
In 1978 after the occurrence of pregnancy-related
deaths associated with, but not limited to, the Dalkon
Shield IUD, the US FDA instructed physicians to remove
an IUD, whenever possible, following an accidental pregnancy. Since implementation of the FDA recommendation, cases of IUD-associated septicemia and septic shock
have become extremely rare. There have been no IUDassociated, pregnancy-related deaths in the US since 1977
(Atrash et al., forthcoming).
Ectopic pregnancy
The Copper T 380 is more effective than most contraceptives in preventing ectopic pregnancy. It does this by
preventing pregnancy. If a pregnancy occurs with the
Copper T 380 in place, it is less likely to be ectopic than
with steroid-releasing IUDs, NORPLANT®, the minipill,
or sterilization and more likely to be ectopic than a pregnancy after the failure of barrier or rhythm methods or
the combined pill.
Women with a history of ectopic pregnancy may
have increased risk of another ectopic pregnancy; women
who have had a pelvic inflammatory disease or sexually
transmitted disease also may have increased risk of an
ectopic pregnancy. If a woman older than 35 becomes
pregnant, she is more likely to experience an ectopic pregnancy than is a younger woman. Women using a copper
IUD whose menstruation is delayed two or more weeks
should immediately visit a clinic or physician to be evaluated for pregnancy and for ectopic pregnancy.
Most IUDs protect against ectopic pregnancy, but
greater protection is offered by the more effective IUDs
such as the Copper T 380. An analysis of 42 randomized
IUD trials of medicated IUDs confirms that both preg-

nancy rates and ectopic pregnancy rates vary inversely
with the surface area of copper on the devices (see Table
5). The more copper, the fewer pregnancies. Ectopic pregnancy ratios in women generally increase with age, but
IUD failure rates decline with age; thus, the annual rate
of ectopic pregnancy both for older and younger users
is about 4 in 10,000 per year or lower. Risks for IUD users depend upon whether the IUD releases copper or a
steroid, the amount released, and the age of the user
(Sivin, 1991b).
Women who use no contraception have a greater risk
of ectopic pregnancy than do copper IUD users. Large
case-control investigations demonstrated that IUD use
significantly reduces a woman's risk of ectopic pregnancy
as compared with the risks of nonusers of contraception
(Oryet al. 1981; WHO, 1985). In these studies the reduction in ectopic pregnancy risk among IUD users was 50
to 60 percent. The IUDs in these studies were far less effective in reducing the incidence of ectopic pregnancy
than the Copper T 380. The Copper T 380 reduces the
risk of ectopic pregnancy by about 90 percent in comparison with nonusers of contraception (Sivin, 1991b).
Expulsion
Expulsion rates of IUDs are typically highest in the first
three months following insertion, and decline thereafter.
Generally, expulsion rates in the second and third years
of use are much lower than in the first year. Gross cumulative expulsion rates from the long-term trials of the
Copper T 380A used in the official labeling of the device
in the United States are shown in Figure 8. In the first
year, the expulsion rate was 5.7 per 100 users.
Many factors affect rates of expulsion. These include

familiarity with the technique of insertion of the particular device and the training, technical skills, and hand
skills of the provider inserting the IUD, the timing of insertion in relation to the preceding pregnancy, the age
of the woman accepting the IUD, and the number of fullterm pregnancies the woman has had.
The technique developed for insertion of Copper T
IUDs differs markedly from that for most other IUDs. IUD
providers must be trained in the specific insertion technique
of the Copper T 380 before attempting placement. The Copper T should be placed at the uterine fundus; proper training helps avoid perforation and partial or complete expulsion by ensuring correct placement.
First-year expulsion rates in randomized studies of
Copper T IUDs are shown in Figure 9. Lower expulsion
rates in more recent studies probably reflect improved
familiarity with the insertion techniques.
The timing of insertion can affect expulsion rates. The
Copper T 380 IUD may be inserted at any time during a
woman's menstrual cycle, provided the woman is not
pregnant and has been consistently using an effective
contraceptive since her last menses. Many clinicians prefer to insert an IUD within seven days of the onset of
menstruation because the cervical opening is slightly dilated during this time, making insertion easier and pregnancy very unlikely. Insertion during these days also is
likely to result in less discomfort, cramping, and/ or spotting for the patient. The most frequent timing of insertion
is interval insertion-three or more months postpartum.
Most of the insertions in the randomized trials of the Copper T 380 conducted in the 1980s were interval insertions.
Insertion after elective first-trimester abortion has been associated with expulsion rates similar to those following interval insertion.

Table 5 Pregnancyand ectopic pregnancyrates per

1,000woman-years in the first 2 years of randomized,
non-postpartumtrials, by copper surface area
Device and
surface area

Woman-years
(OO0s)

All

53.4

Figure 8: Gross cumulative expulsion rate per 100 Copper T
380A users, through 8 years
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Figure 9: First-year gross expulsion rates per 100 users
for the Copper T 380 in randomized trials
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Immediate post-placental IUD insertion before the
woman leaves the delivery room is associated with expulsion rates that have not been lower than 10 per 100 at one
year, and have reached 41 to 46 per 100. They show remarkable variation by clinic, reflecting the skill and experience
of the healthcare provider. In the most recent study of the
Copper T 380 inserted within ten minutes after spontaneous expu lsion of the placenta, Van Kets and colleagues
(1991) report ed a one-year gross expulsion rate of 13.3 per
100. Among the four clinics participating in the study, the
range of the one-year expulsion rate was 3.8 to 45.7 per 100.
Studies of insertions of the Copper T 380 more than ten minutes after delivery of the placenta but before hospital discharge have not been reported.
.
Insertion of the Copper T 380 in the second postpartum month has been associated with low rates of expulsion in the six-month period following (Chi et al., 1989;
Mishell & Roy, 1982) and in the year following (Population Council data). Insertion during the second postpartum
month may have programmatic and personal advantages,
as many women visit a provider for a six-week postpartum check-up .
Bleeding and pain

In the initial years of use, menstrual problems and pain constitute the major single reason for remova l of the Copp er T
380 IUD. Similar findings apply to other IUDs (Rybo, forthcoming). The combined Population Council 1972-1976 and
WHO data in the US labeling show gross cumulative termination rates for bleeding and pain as 11.9 per 100 users
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in the first year and 20.6 at two years. Termination rates
attributable to menstrual problems and pelvic pain vary
inversely with both age and parity. The first two randomized studies of the Copper T 380A (Sivin and Stern, 1979;
Roy et al., 1979) included a majority of women under age
25 who were nulliparous. Women with these characteristics tend to have the highest rates of IUD removal. Thus,
the early studies showed relatively high rates of removal
for bleeding and pain and led to the belief that high rates
of bleeding and pain are associated with the Copper T 380
ruo, as compared to other IUDs.
Thirteen years after those early publications, numerous randomized trials of the Copper T 380 show something
quite different. Few nulliparous women have participated
in randomized trials initiated in 1979 or later. In consequence, rates of removal of the Copper T 380 for menstrual
problems and/ or pain in ten later randomized trials were
less than half the rates reported by Roy et al. or Sivin and
Stern in 1979 (Table 6).
Users of the Copper T 380 had lower rates of removal
for menstrual problems or pain than did users of non-T devices in seven of ten one-year randomized comparisons
with non-T IUDs.

Table 6 First-yeargross removal rates per 100 woman-

years attributedto menstrualproblemsand/or pain, in
randomizedcomparativetrials
Firstauthor
Non-medicatedIUDs
Diaz
Chi
Sastrawinata
Sung

TCu380
rate

Otherdevice
Rate Name

5.9
3.1
1.6
7.4•

10.7
4.9
1.9
4.8

Lippes Loop D
Lippes Loop D
Lippes Loop D
Mahua

1.5
3.6
1.6
3.1
6.0·
7_5•

2.0
3.6
1.1
4.2
10.4"
14.7"

MLCu 250
MLCu 375
MLCu375
Cu?
LNg20
LNg20

12.9
3.2
6.9
15.6
1.5
6.3
3.6
6.8

TCu 200
TCu200
TCu200
TCu 220C
TCu220C
TCu220C
Tcu 220c
TCu220C

OthermedicatedIUDs
(not CopperT)
Chi
Cole, Champion
Sastrawinata
Cole, Apelo
Sivin
Saxena (ICMR)

CopperT IUDs
Sivin and Stern
Chi
Saxena
Roy
Chi
Rowe, Farley (WHO)
Sung
Saxena

15.6*
6.6
7.5
16.3
0.9
5.9
7.4•
7.5

•The difference between these rates is statistically significant at p<.05 .
"Terminations attributable to amenorrhea are included .

Comparisons of the Copper T 380 with the other Copper T models show few substantial differences. Reviewing
the published data, Rowe (forthcoming) concluded that it
is unlikely that important differences exist among standard
copper IUDs available today with respect to removal rates
for bleeding/pain problems.
Annual rates of removal for bleeding and pain are highest in the initial year of use and decline thereafter. In the
first year, the rate was 7.7 per 100 woman-years for all variants. This decreased to 6 per 100 woman-years in the second year of use. In years three through eight the rate varied narrowly between 3 and 4 per 100.
As with other nonhormonal IUDs, users of the Copper T 380A experience, on average, increased menstrual
blood loss (MBL) in the initial year. Copper IUD use may
induce iron deficiency in some women. Programs should
be prepared to treat iron deficiency then or before a
woman is given an IUD. In a short-term study (Gallegos
et al., 1978), the average increase in blood loss was approximately 43 ml, accompanied by a significant decrease
of hemoglobin. In a longer term study of the Copper T
220, MBL diminished with time (Andrade and Pizaro,
1987), and by the end of two years of its use, MBL was
not greatly elevated above baseline. A study of the Copper T 380Ag (Sivin et al., 1984) showed an average decrease in hemoglobin of 3.6g/L at one year of use and of
1.3g/L in the first two years. After the first two years,
however, continuing users of the Copper T 380Ag IUD
experienced modest increases in hemoglobin that were
statistically significant when compared with their status
at two years of use (Sivin et al., 1991b), or at admission.

Other medical reasons for removals
Clinical studies record all medical reasons women give
for removal of an IUD; some may be method-related,
some not. In the US FDA-approved labelling for the Copper T 380A, gross cumulative medical terminations for
reasons other than bleeding or pain were 2.5 per 100 users at one year, 5.9 per 100 users at three years, 7.6 at
five years, and 9.0 at eight years.
A detailed tabulation of reasons for termination during the first two years of the first large Council study is
given in Table 7. The overall rate of medical removals
for the two-year period was 3.17 per 100 woman-years
of exposure. Pelvic inflammatory disease and endometritis (1.27 per 100 woman-years) and vaginitis (0.46
per 100 woman-years) were the principal "other medical" removals during the first two years. Apart from these
two, no single condition had a removal rate above 0.2
per 100 woman-years. Accidental removals and reported
discomfort to the IUD user's husband caused by the IUD
strings ranked third and fourth, respectively, in rate of
removal.

IUD use and pelvic inflammatory disease (PID)

From the very first, the relationship of IUDs to pelvic inflammatory disease (PID) has received substantial attention. Studies of the possible association multiplied in the
1970s in the US in the wake of problems related to the
Dalkon Shield, a plastic IUD introduced in 1971.
IUD use has been associated with increased risk of
PID in the first one to four months of use, with the risk
highest just after insertion of the device due to the insertion process itself. Insertion of an IUD may introduce microorganisms from the vagina into the uterus. To minimize the possibility of infecting the upper reproductive
tract, insertion must be performed under strict aseptic
procedures. Risk of PID thereafter is associated with exposure to sexually transmitted diseases (STDs). Infections
of the uterus or adnexa caused by sexually transmitted
organisms or other infectious agents are called PID. Rates
of PID vary enormously, depending on the age and parity of the women, the degree of mutual monogamy practiced, the frequency of medical observation, and criteria
used to diagnose or characterize PID. Any person can
be exposed to sexually transmitted diseases by having
multiple sex partners, or having a partner who has multiple sex partners. IUDs are most appropriate when exposure to sexually transmitted disease is minimal, that

Table 7 Pearl rates of terminationfor medical reasons

other than bleeding and pain during first two years of use
of the Copper T 380A IUD (3,536 acceptors), US
1972-1975
Reason

Rate per 100
woman-years

Total

3.17

Pelvic inflammatory disease a
Vaginitis, etc.
Perforation of uterus
Perforation of cervix
Internal displacement
Carcinoma of cervix
Abnormal cytology
Ovarian cysts
Fibroids
Other genital pathology

1.27
0.46
0.05
0.14
0.05
0.02
0.12
0.17
0.02
0.02

Diseases of urinary tract
Surgery
Psychiatric problems
Miscellaneous medical problems
Discomfort to husband
Pregnant at admission
Unintended or erroneous removal
by patient or physician

0.05
0.02
0.05
0.31
0.12
0.05
0.24

Sivin and Stern, 1979.
"Includes PIO, salpingitis, and endometritis.
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is, for women in stable, mutually monogamous relationships. Women in such relationships are at minimal risk
of PID, whether or not they use an IUD (Lee et al., 1983,
1988;Stone et al., 1986; Struthers, 1985).In a major analysis from the US Women's Health Study (WHS), conducted from 1976-1978, currently married or cohabiting
IUD users with only one partner did not have a significantly increased PIO risk compared with monogamous
women using no method of family planning (Lee et al.,
1988).
Case control studies have provided an opportunity
to estimate the relative risk of PIO among IUD users in
comparison with women from the same population
groups who have used no contraception. Burkman et al.
(1981) and Lee et al. (1983) found in the WHS that women
using various IUDs (excluding the Dalkon Shield) were
1.6 times more likely to develop PIO than were women
using no contraception. In the first month after insertion,
they were four times more likely to develop PID. Two to
four months after insertion, the relative risk decreased
in non-Dalkon Shield users. Thereafter, IUD users were
not at significantly higher risk of developing PID than
were women using no method. A case-control study conducted by the WHO in 12 developing countries found
that parous IUD users were 2.3 times more likely to develop PIO than were women using no contraception
(WHO, 1984). The same case-control study at three developed country sites also found an elevated relative risk
of 4.1 for parous IUD users.
In the 1972-1976 Population Council clinical trials
of the Copper T 380A, the termination rate for PID was
1.27 per 100 woman-years in the first year. The rate decreased to 0.71 per 100 woman-years in the second year
and to 0.0 per 100 woman-years in the third year of use.
The majority of women in this study were under age 25
and nulliparous. In marked contrast, in the eight year
WHO study of the Copper T 380A, undertaken principally in traditional, developing country settings, there
were no reported cases of PIO in the first two years of
use. The overall rate of occurrence (and termination) due
to PID in the WHO study was minuscule, 0.05 per 100
woman-years (WHO data submitted to the FDA). In all
WHO studies of the Copper T 380A, the rate has been
0.05 per 100 woman-years (Farley et al., 1992), about six
percent of the rate of 0.93 per 100 found in the first three
years of use in the US studies of the early 1970s (Sivin
and Stern, 1979).
Some physicians may consider use of the prophylactic administration of antibiotics before insertion. There
is no evidence from studies that such administration is
beneficial in preventing PID. A Nigerian study (Ladipo
et al., 1991) compared a dose of 200 mg of doxycycline
with a placebo, and found no significant difference in
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PID rates between regimens. Indeed, the placebo-treated
regimen had the lower observed rate. The investigators
concluded that emphasis on aseptic conditions during
IUD insertion, follow-up visits with short intervals to
monitor health, and treatment of opportunistic infections
may have reduced the potential of PID within this population. Sinei et al. (1990) studied the efficacy of prophylactic doxycycline at insertion in a large randomized clinical trial in Kenya, but also did not find a statistically
significant difference in PIO rates between the group
given antibiotics and those given a placebo. Given the
negative findings of these two studies, some argue that
routine use of prophylactic antibiotics at IUD insertion
would burden the method with additional costs without providing a benefit.
Uterine or cervical perforation
Although rare, partial or total perforation of the uterine
fund us or cervix may occur following insertion of a Copper T 380 IUD (Sivin and Tatum, 1981). In the initial
Population Council study of the Copper T 380 IUD, two
uterine perforations---one associated with pregnancywere reported among 3,536 women. Apart from unintended pregnancy, the consequences of uterine fundal
perforation can be severe. The IUD may cause adhesions
or may puncture organs in the peritoneal cavity, or cause
sepsis if the bowel is punctured. The consensus treatment
is to remove copper devices that have perforated the
uterus and provide an alternative contraceptive method,
if desired .
There is evidence (Tietze and Lewit, 1970) that the
risk of fundal perforation is greater early in the postpartum period before the uterus is fully involuted. Special
care is required when inserting postpartum, whether or
not the woman is lactating. This has been discussed by
Heartwell and Schlesselman (1983) and Sivin (1984).Further discussion of insertion while the woman is breastfeeding appears below under Lactationand IUD use. Insertion of the Copper T 380 or any other IUDs in the first
two to three months postpartum is best done only by
highly trained providers.
Cervical perforation is believed to be a more common phenomenon than uterine perforation. This appeared to be the case in the initial studies of Copper T
devices when the Copper T 380A was manufactured
without the ball tip. Six cervical perforations among 3,536
women were reported (Sivin and Stern, 1979). Cervical
perforations usually occurred in conjunction with partial expulsion of the IUD. When the US FDA approved
the Copper T 200 in 1976, it required that the polyethylene be molded into a bulb and placed at the lower vertical tip of the IUD to reduce the likelihood of cervical perforation. It is believed that this bulb lowered the rate of

cervical perforation of these two IUDs.
In all randomized trials of the Copper T 380, the rate
of uterine perforations was 0.4 per 1,000 women and the
rate of cervical perforation was 0.6, based on 9,521
women.

Allergy
There have been few cases of allergy associated with use
of a copper IUD. A study of 1,121 users of Copper T 380
IUDs over an average of four years of use reported no
cases of allergy to copper (Population Council data).

Continuation rates and acceptability
Continuation rates are one indication of the acceptability of a method after its use has been initiated. Continuation rates of IUD users are among the highest found in
users of modern reversible contraceptives, including implants, oral contraceptives, and injectables (Trussell et al.,
1990).
Cumulative continuation rates for the Copper T 380A
used in the FDA-approved labeling are shown in Figure
10. The continuation rate was 77 per 100 users at one year.
At the end of six years, 35 per 100 of the original acceptors were continuing, and at the end of eight years, 28.5
percent were still using the same IUDs. Average duration of use is 3.85 years . For the Copper T 380Ag in the
Population Council study, the one year continuation rate
was 82 per 100. At the end of eight years, 25 per 100
women were still using their original Copper T 380 (Sivin
et al., 1990a, and Population Council data).
One-,two-, and three-year continuation rates in each
of the randomized studies of the Copper T 380 variants
are shown in Table 8. In six of the seven published threeyear trials, the cumulative continuation rate at three years
was 50 per 100 women or higher.
Because younger women and those with no children
or only one child are more likely to want additional children, continuation rates vary with age and parity. Continuation rates also vary remarkably with the setting of
the study or family planning program. The rates depend
on the attitudes and experiences of the users, the attitudes and skill of the providers, as well as on the degree
of availability of other methods of highly effective, reversible contraception. Hardy and Goodson (1991) have
shown an association between the contraceptive method
accepted and the perception of the information received
during counseling.
IUDs are the most popular reversible method worldwide. Nevertheless, acceptance of the method varies from
country to country . From 20 percent to 40 percent of
contraceptors in Scandinavia use IUDs. In China, where
over 65 million women choose from a selection of steel

rings and copper IUDs, the method is a favored contraceptive; over 40 percent of Chinese contraceptive users
choose IUDs. Other countries with large percentages of
IUD users among all contraceptive users include Vietnam, Jordan, Egypt, Tunisia, and Indonesia. IUDs also
are popular in Germany, Mexico, Turkey, Taiwan, and
Hungary (Mauldin and Segal, forthcoming). American
women's attitudes about the IUD have changed dramatically from the early 1970s, when four in ten married
women viewed the method with favor. In 1991, US
women were more likely to have an unfavorable attitude
about IUDs than about any other method then available
(Forrest, 1992). This reflects the adverse publicity given
to all IUDs because of concerns with the safety of the
Dalkon Shield. However, the 1991 Ortho Annual Birth
Control Study showed that among those using the IUD,
the proportion reporting satisfaction with the method is
higher than among users of any other method (Ortho,
1991).

Return to fertility
Reversible contraceptives should not impede the speed
at which women become pregnant or have children after they stop contracepting. Tietze and Lewit (1970)
showed that, for a variety of nonmedicated IUDs,
lifetable estimates of pregnancy rates were close to the
values demographers considered normal. Vessey and
colleagues (1976) in Oxford found that in the two years
after removal for planned pregnancy, birth rates among
former users of IUDs were as high or higher than among
women using combined oral contraceptives or barrier
methods.

Figure 10: Cumulative continuation rates for Copper T 380A
IUD per 100 users, through 8 years
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Table 8 Cumulativecontinuationrates per 100 women in

randomizedstudies
Authors
TCu380A
Sivin and Stern
Roy et al.
Diaz et al.

WHO
Sastrawinata
Sivin et al.

TCu380Ag
Champion et al.
Apelo et al.
Sung et al.
Sivin et al.
Saxena (ICMR)

Year1

Year2

69.7
72.1
82.5
86.7
90.3
79.7

5p.1
50.0
75.6
85.5
68.9

66.4

89.5
85.6
88.4
81.8
83.5

79.7
80.8
83.9
69.0
69.9

67.4
74.3
75.8
59.3
50.4

Figure 11: Cumulative rate of planned pregnancy after
removal of Copper T 380
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Studies of the Copper T 380A and Ag also indicate
normal pregnancy rates after IUD removal and normal
pregnancy outcomes. In a study with substantial loss to
follow-up, 80.3 per 100 parous women who had used the
Copper T 380A became pregnant within a year of removal of their IUD as did 76.1 per 100 nulliparous
women (Sivin and Stern, 1979). Limiting analysis to clinics with good follow-up, Belhadj et al. (1986) and Sivin
et al. (1986) showed that the pregnancy rates of former
Copper T 380Ag users were normal at one and two years
(see figure 11). Sivin et al. (1992) also showed that the
rates of successful planned pregnancy were unaffected
by duration of use. Age at IUD removal for planned pregnancy was a significant factor affecting rates; women who
were 30 years of age or older at IUD removal had substantially lower rates of planned pregnancy than did
younger women. This is also true in the general population. Women who said they wanted more children at the
time of IUD insertion had significantly higher pregnancy
rates post-removal than did women who were not sure,
or who thought they wanted no more children but subsequently removed the IUD (Sivin et al., 1992).Pregnancy
rates following removal of the Copper T 380Ag were
similar at one and two years to those observed among
women with NORPLANT® capsule or rod implants.
Studies that follow cohorts of women desiring pregnancy do not provide a complete picture of the effects of
IUDs or other contraceptives on the reproductive capacities of former users. Because women with PID,· endometritis, accidental ectopic pregnancy, or other conditions that may compromise future fertility are not
included in the group of women followed for a planned
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pregnancy, rates of successful planned pregnancy may
be overstated. To address that problem, several investigators have studied women who removed IUDs following a "complication" of use, and then sought pregnancy,
as well as removals for planned pregnancy. All the cohorts studied (Sandmire, 1986; Skjeldestad, 1988; and
Wilson, 1989), no matter which group they were from,
were deemed to have normal pregnancy rates.
A different approach has been taken in case-control
studies of tubal infertility. The concern has been that with
elevated risks of PID, IUD users may also have increased
risks of tubal infertility. The study groups have consisted
of women who sought medical help to overcome infertility of one year's duration (Cramer et al., 1985; Daling
et al., 1985; Daling et al., 1992). These studies found that
the risk of primary tubal infertility varied with both the
type of IUD and the number of sexual partners the
women had. The studies of Daling and Cramer, taken
together, now indicate a significantly increased risk of
primary tubal infertility among women with copper devices then used in the US (principally the Copper 7 IUD).
But these case-control studies suffer from the same limiting features as do the cohort studies of planned pregnancy. The women who sought medical help for fertility are self-selected from among upper economic groups.
At the time of the studies, it was widely believed that
IUDs might affect future fertility, and so women with
IUDs might have sought medical evaluation more frequently than their peers, thereby introducing a bias in
the results, as Skjeldestad has shown. Non-response or
refusal to be interviewed or give data reached 30 percent. Whatever their exact merit, these studies strongly
suggest that an IUD is not the method of first choice for
nulliparous women.

Table 9 Insertionevent rates per 1,000women by breastfeedingstatus
Status at Insertion
Breastfeeding

Women

Nonbreastfeeding

Women

Probability

0.0
2.7
0.0
1.3

559
744
222
1,525

0.0
0.0
0.0
0.0

590
203
773
1,566

NS
NS
NS
NS

Moderateor severe pain
at insertion
Chi et al.
Sivin et al.

8.9
45.0

559
222

27.1

590

99.6

773

<.05
<.05

All insertionevents*
Chi et al.

16.1

559

47.5

590

<.01

Events/Authors
Uterine perforation
Chi et al.
Sastrawinata
Sivin et al.
Total

*lnduded cervical laceration,dilatationrequired,and uterineperforation.

Lactation and IUD use
IUD use does not decrease either the quantity or quality
of breastmilk in lactating women (Labbok, 1985).Because
it does not affect breastmilk, a woman may choose to initiate IUD use while nursing her baby. During breastfeeding, contraception with combined oral pills is not recommended, because the estrogen component of the pills
is known to affect the quantity and quality ofbreastmilk.
Chi and colleagues (1989a) investigated insertion events
and termination event rates in breastfeeding
and
nonbreastfeeding women using the Copper T 380. Sivin
and colleagues (1990b) and Sastrawinata and colleagues
(1991) also compared Copper T 380 insertion and termination events and rates. Data from each of these studies
and their combination appear in Table 9 as do data on
perforation rates from an on-going Population Council
study of IUDs.
The FHI investigators found significantly lower rates
of required dilation and of moderate or severe pain at
IUD insertion in the breastfeeding women, as compared
with nonbreastfeeding women. There were no uterine
perforations in either group. At six months of use, breastfeeding women had significantly lower rates of removal
for bleeding and pain and higher continuation rates, al-

though it is not clear how much of these differences derive from different starting points within pregnancy intervals.
The findings in the Population Council study of the
Slimline and Gyne T*380 were similar to Chi's with respect to a significant reduction in the occurrence of moderate or severe pain at insertion in the breastfeeding
group and the absence of perforation in either group.
In the context of a multicenter randomized trial in Indonesia, Sastrawinata and colleagues (1991) showed that
neither expulsion nor removal rates for bleeding and pain
were elevated when use of a Copper T 380A IUD was initiated during breastfeeding, and the latter rate may be reduced in comparison with insertion at other times. There
were, however, two uterine perforations in the breastfeeding group . (See Uterine Perforation section.)
Overall rates of moderate or severe insertion pain
were signific antly low er in the br eastfeedi ng gro ups .
Rates of perforatio n we re no t sign ifican tly higher in these
comparative studies, but that these rare events requiring surgical removal of the IUD occurred at all to lactating women places emphasis on the great need for skilled
care in inserting an IUD at this juncture.

21

BIBLIOGRAPHY
This compendiumof articlesand studies containsour selection
ofcoreworkdoneon theCopperT IUD from the60sto thepresent,
as wellas themost highlyregardedresearchon thesubject.Those
articlescitedin the text aremarkedby an(*).

Adoni, A. and A. Ben Chetrit. 1991. "The management of intrauterine
devices following uterine perforation." Contraception43,1: 770-781.
*Alvarez, F., V. Brache, E. Fernandez, B. Guerrero, E. Guiloff, R. Hess,
A.M. Salvatierra, and S. Zacharias. 1988. ''New insights on the mode
of action of intrauterine contraceptive devices in women." Fertility
and Sterility 49,5: 768-773.
American College of Obstetricians and Gynecologists. 1974. Technical
Bulletin:The IntrauterineDevice.Chicago.
_.

1992. TechnicalBulletin:The intrauterinedevice.No. 164. Washington, DC.

The American Medical Association. 1989. "Diagnostic and therapeutic technology assessment (DATI A), intrauterine devices." Journal
of the AmericanMedicalAssociation261,14: 2,127-2, 130.
*Andrade, A.T.L. and E. Pizarro Orchard. 1987. "Quantitative studies
on menstrual blood loss in IUD users." Contraception36, 1: 129-144.
*Apelo, R.A., R.M. Ramos, E. Bernardo, and C.B. Champion. 1989. "A
3-year evaluation of the TCu 380Ag and the Cu-7." International
Journalof Gynecologyand Obstetrics28,3: 269-273.
•Aref, I., 0. Kandi!, A. El Tagi, and M.R. Morad. 1983. "Effects of nonmedicated and copper IUDs on sperm migration." ContraceptiveDelivery Systems 4,3: 203-206.
•Atrash, H.K., A. Fry, and C.J.R. Hogue. Forthcoming. ''Incidence of
morbidity and mortality with IUD in situ in the 1980s and 1990s."
In Proceedings of A New Look at IUDs -Advancing Contraceptive
Choices,eds. C.W. Bardin and D.R. Mishell, Jr. Boston: ButterworthHeinemann.
Bardin, C.W. and D.R. Mishell, Jr., eds. Forthcoming. Proceedingsof A
New Look at IUDs -Advancing Contraceptive Choices. Boston:
Butterworth-Heinemann.
*Belhadj, H., I. Sivin, S. Diaz, M. Pavez, A.-S. Tejada, V. Brache, F.
Alvarez, D. Shoupe, H. Breaux, D.R. Mishell, Jr., T. McCarthy, and
V. Yo. 1986. "Recovery of fertility after use of the levonorgestrel 20
mcg/ d or Copper T 380Ag intrauterine device." Contraception34,3:
261-267.
Eerie, B., S. Aleksic, M. Marjanovic, and F. Kranz. 1985. ''Notre
experience du Gyne-T Cu 380A, dispositif intra-uterin (1981-1984)."
Contraception,Fertilite,Sexualite 13,5: 717-719. (Abstract in English,
ContraceptiveDeliverySystems 5,3: Abstract 66.)
Buchan, H., L. Villard-Mackintosh, M. Vessey, D. Yeates, and K.
McPherson. 1990. "Epidemiology of pelvic inflammatory disease
in parous women with special reference to intrauterine device use."
BritishJournalof Obstetricsand Gynaecology97,9: 780-788.

stetricsand Gynecology57,3: 269-276.
*Champion, C.B., B. Behlilovic, J.M. Arosemena, L. Randie, L.P. Cole,
and L.R. Wilkens. 1988. "A three-year evaluation of TCu380Ag and
Multiload Cu 375 intrauterine devices." Contraception38,6: 631---639.
*Chang, C.C. and H.J. Tatum. 1973. "Absence of teratogenicity of intrauterine copper wire in rats, hamsters and rabbits." Contraception 7,5: 413-434.
*Chi, I.-C. 1985. "IUD use in diabetic or lactating women or women
after cesarean delivery - An epidemiological perspective." Advancesin ContraceptiveDelivery Systems. Monograph 2: 287-297.
Chi, I.-C. 1991. "An evaluation of the levonorgestrel-releasing IUD:
Its advantages and disadvantages when compared to the copperreleasing IUDs." Contraception44,6: 573-587.
Chi, LC. and G. Farr. 1989. "Postpartum IUD contraception: A review
of an international experience." Advances in Contraception5,3: 127146.
*Chi, L-C., G. Farr, K. Thompson, M. Acosta, G. Alvarado, R. Rivera,
J. Bandaragoda, and J.D. Betancourt. 1990. "Is the Copper T 380A
device associated with an increased risk of removal due to bleeding and/ or pain?: An analysis." Contraception42,2: 159-169.
Chi, LC. and E. Kelly. 1984. "Is lactation a risk factor of IUD- and sterilization-related uterine perforations?: A hypothesis." International
Journalof Gynaecologyand Obstetrics22,4: 315-317.
•Chi, I.-C., M. Potts, L.R. Wilkens, and C.B. Champion. 1989a. "Performance of the Copper T-380A intrauterine device in breastfeeding women." Contraception39,6: 603---618.
*Chi, L-C., L.R. Wilkens, C.B. Champion, R.E. Machemer, and R.
Rivera. 1989b. "Insertional pain and other IUD insertion-related
rare events for breastfeeding and non-breastfeeding women: A
decade's experience in developing countries." Advancesin Contraception5,2: 101-119.
Cole, L.P., M.F. McCann, J.E. Higgins, and C.S. Waszak. 1983. "Effects of breastfeeding on IUD performance." American Journalof
PublicHealth73,4: 384-388.
*Cole, LP., D.M. Potts, C. Aranda, B. Behlilovic, E.-S.Etman, J. Moreno,
L. Randie, R. Apelo, and M. Thomas. 1985. "Comparative copper
IUD trials." In Intrauterinecontraception:Advances and future prospects,eds. G.I. Zatuchni, A. Goldsmith, and J.J. Sciarra, pp. 95-100.
Philadelphia: Harper & Row.
*Cramer, D.W., L Schiff, S.C. Schoenbaum, M. Gibson, S. Belisle, B.
Albrecht, R.L Stillman, M.J. Berger, E. Wilson, B.V. Stadel, and M.
Seibel. 1985. "Tubal infertility and the intrauterine device." New
EnglandJournalof Medicine312,15: 941-947.
*Daling, J.R., N.S. Weiss, B.I. Metch, W.H. Chow, R.M. Soderstrom,
D.E. Moore, L.R. Spadoni, and B.V. Stadel. 1985. "Primary tubal
infertility in relation to the use of an intrauterine device." New Eng landJournalofMedicine312,15: 937-941.
•Dating, J.R., N.S. Weiss, L.F. Voight, B. McKnight, and D.E. Moore.
1992. "The intrauterinedevice and primary tubal infertility." Letter to the Editor. New EnglandJournalofMedicine326,3:203-204.

Burkman, R.T., N.C. Lee, H.W. Ory, and G.L. Rubin. 1991. "Response
to 'The intrauterine device and pelvic inflammatory disease: The
Women's Health Study reanalyzed."' Journalof ClinicalEpidemiology 44,2: comment 123-125; discussion 211-213.

DaVanzo, J., A.M. Parnell, and W.H. Foege. 1991. "Health consequences of contraceptive use and reproductive patterns." Journal
of the AmericanMedicalAssociation265,20:2,692-2,696.

*Burkman, R.T. and The Women's Health Study. 1981. "Association
between intrauterine device and pelvic inflammatory disease." Ob-

*Diaz, J., M.M. Diaz, L. Pastene, R. Araki, and A. Faun des. 1982. "Randomized clinical study of the T-Cu 380A and the Lippes Loop C,

23

in Campinas, Brazil. Contraception26,3: 221-228.
Diaz, S., M. Pavez, H. Cardenas, and H.B. Croxatto. 1987. "Recovery
of fertility and outcome of planned pregnancies after the removal
of NORPLANT® subdermal implants or Copper-T IUDs." Contraception35,6: 569-579.

*Holland, M.K. and I.G. White. 1988. "Heavy metals and human spermatozoa: III. The toxicity of copper ions for spermatozoa." Contraception38,6: 685-695.

Edelman, D.A. and W.A.A. van Os. 1990. "Safety of intrauterine contraception." Advancesin Contraception6,3: 207-217.

*Indian Council of Medical Research, Task Force on IUD. 1989. "Randomized clinical trial with intrauterine devices Oevonorgestrel intrauterine device (LNG), CuT 380Ag, CuT 220C and CuT 200B): A
36-month study.'' Contraception39, 1: 37-52.

*Evans, U.R. 1960. The corrosionand oxidationof metals:Scientificprinciplesand practicalapplications.London: Edward Arnold Ltd.

Jain, A.K. and I. Sivin. 1977. "Life-table analysis of IUDs: Problems and
recommendations.'' Studiesin FamilyPlanning8,2: 26-47.

*Farley, T.M.M., P. Rowe, 0. Meirik, M.J. Rosenberg, and J.-H. Chen.
1992. "Intrauterine devices and pelvic inflammatory disease: An international perspective.'' Lancet339: 785-788.

Jouppila, P., A. Niinimaki, and M. Mikkonen. 1979. "Copper allergy
and copper IUD.'' Contraception19,6: 631-637.

Food and Drug Administration. 1991. CopperT 380A Labelling.Washington, D.C.: United States Food and Drug Administration.

Kooiker, C.H. and F.D. Scutchfield. 1990. ''Barriers to prescribing the
Copper T 380A intrauterine device by physicians.'' WesternJournal
of Medicine153,3: 279-282.

Forck, G., H. Kastner, and H. Wagner. 1977. "One case of allergic reaction due to Copper T." Paper read at II. International Symposium
on Contact Dermatitis, 14-15 March 1977, in Elsinore, Denmark.

*Kosonen, A. 1980. "Corrosion of copper in utero.'' In MedicatedIntrauterineDevices,eds. E.S.E. Hafez and W.A.A. van Os, pp. 22-29. The
Hague: Martin us Nijhoff.

•Forrest, J .D. Forthcoming. "Acceptability of IUDs in the United States."
In Proceedings
ofA Nw Lookat IUDs -AdvancingContraceptiveChoices,
eds. C.W. Bardin and D.R. Mishell, Jr. Boston: BullerworthHeinemann.

Kronmal, R.A., C.W. Whitney, and S.D. Mumford. 1991. "The intrauterine device and pelvic inflammatory disease: The Women's Health
Study reanalyzed." Journalof ClinicalEpidemiology44,2: 109-122.

Franks, A.L., V. Beral, W. Cates Jr., and C.J.R. Hogue. 1990. "Contraception and ectopic pregnancy risk." AmericanJournalofObstetrics
and Gynecology163,4: 1,120-1,123.

*Labbok, M.D. 1985. "Contraception during lactation: Considerations
in advising the individual and in formulating programme guidelines.'' Journalof BiosocialScienceSupplement 9: 55-56.

Frentz, G. and D. Teilum. 1980. "Cutaneous eruptions and intrauterine contraceptive copper device.'' Acta Dermatovener60: 69-71. Published in Stockholm.

*Ladipo O.A., G. Farr, E. Otolorin, J.C. Konje, K. Sturgen, P. Cox, and
C.B. Champion. 1991. "Prevention of IUD-related pelvic infection:
The efficacy of prophylactic doxycycline at IUD insertion.'' Advances
in Contraception7,1: 43-54.

*Gallegos, A.J., R. Aznar, G. Merino, and E. Guizer. 1978. "Intrauterine
devices and menstrual blood loss: A comparative study of eight devices during the first six months of use.'' Contraception17,2: 153-161.

•Lee, N.C., G.L. Rubin, and R. Borucki. 1988. "The intrauterine device
and pelvic inflammatory disease revisited: New results from the
Women's Health Study." Obstetricsand Gynecology72,1: 1-6.

Gao, J., S. Zeng, B. Sun, S. Wu, J. Dong, J. Cong, X. Zhu, H. Fan, L.
Han, and Z. Xie. 1986. "Menstrual blood loss, hemoglobin and ferritin concen !ration of Beijing women wearing Steel Ring, VCu 200,
and TCu 220C IUDs." Contraception34,6: 559-571.

*Lee, N.C., G.L. Rubin, H.W. Ory, and R.T. Burkman. 1983. "Type of
intrauterine device and the risk of pelvic inflammatory disease."
Obstetricsand Gynecology62,1: 1-6.

Goh, T.H. and S.L. Tong. 1986. "Patterns of copper loss: A comparison
of the Multiload Cu250, TCu-220C and Cu7 IUDs." Contraception
33,4: 411-420.
Goluda, M. and J. Lembas. 1985. "Uwalnianie miedzi z antykoncepcyjnych
wkladek wewnatrzmacicznych
Copper T200.''("Copper release from the contraceptive intrauterine device
Copper T 200.'') WiadLek38, 13: 933-936.
Gray R.H. 1985. "A case-control study of ectopic pregnancy in developed and developing countries." In IntrauterineContraception:
Advancesand Future Prospects,eds. G.I. Zahlchni, A. Goldsmith, and
J.J. Sciarra, pp. 35W64. Philadelphia: Harper & Row.
Hardel, P.J. andJ. Tisserand 1984. ''Eczema aigu apres pose d'un sterilet
au cuivre.'' LaPresseMidicale13,31: 1,900-1,901.
*Hardy, E. and P. Goodman. 1991. "Association between contraception method accepted and perception of information received: A
comparison of NORPLANT® and IUD acceptors." Contraception
43,2: 121-128.
Hausen, B.M. and W. Hohlbaum. 1986. "Verursachen
kupferintrauterinpessare eine kontaktallergie?" ["Do copper intrauterine
devices cause contact allergy?"] DeutschemedizinischeWochenschrift
111,26: 1,016-1,021.
*Heartwell, S.F. and S. Schlesselman. 1983. "Risk of uterine perforation among users of intrauterine devices." Obstetricsand Gynecology 61,1: 31-36.

24

Lombardi, P., P. Campolrni, and A. Sertoli. 1983. "Lichenoid dermatitis
caused by nickel salts?" ContactDermatitis9,6: 520-521.
Martinez, J.T., A.L. Munoz, G. Garcia, 0. Martinez, and M. Marfn. 1978.
"Evaluaci6n de Ires tipos de dispositivos intrauterinos portadores
de cobre: Estudio comparativo con el Lippes D. Rev. de Obstetriciay
Ginecologfa38,1:
67-69.
•Mauldin, W.P. and S.J. Segal. Forthcoming. "IUD use throughout the
world: Past, present and future.'' In Proceedingsof A New Lookat
IUDs - AdvancingContraceptiveChoices,eds. C. W. Bardin and D.R.
Mishell, Jr. Boston: Butterworth-Heinemann.
The Medical Device and Drug Advisory Committee on Obstetrics and
Gynecology. 1978. SecondReporton IntrauterineContraceptive
Devices.
Washington, D.C.: United States Food and Drug Administration.
The Medical Letter. 1988. "New Copper IUD.'' Vol. 30, Issue 760: 2528.
*Mishell, D.R., Jr. and S. Roy. 1982. "Copper intrauterine contraceptive device event rates following insertion 4 to 8 weeks postpartum.'' AmericanJournalof Obstetricsand Gynecology143,1: 29-35.
*Moo-Young, A.J. 1972. "Accumulation of copper in certain tissues of
rats with copper intrauterine devices and abdominal copper inserts." Unpublished manuscript.
•Moo-Young, A.J., H.J. Tahlm, A.O. Brinson, and W. Hood. 1973. "Copper levels in tissues of Rhesus monkeys bearing in Irauterine or intraabdominal copper devices." Fertilityand Sterility 24,11: 846-853.
*Moreno, L. and N. Goldman. 1991. "Contraceptive failure rates in de-

veloping countries: Evidence from the demographic and health surveys." InternAtionalFamilyPlanning Perspectives17,2: 44-49 .
Mosher, W.D. and W.F. Pratt. 1990. "Use of contraception and family
planning services in the United States, 1988." AmericanJournalof
PublicHealth 80,9: 1132-1133.
•O'Hanley, K. and D.H. Huber. 1992. "Postpartum IUDs: Keys for success." Contraception45, 4: 351-361.
•Ortho Pharmaceutical . 1986. "Determinat ion of Corrosion Rates for
'Control' and 'Oxidized ' Copper Wires and Cylinders." Technical
report .
•Ortho Pharmaceuticals . 1991.1991 OrthoAnnual Birth ControlStudy.
•Ortiz, M.E. and H.B. Croxatto. 1987. 'The mode of action of IUDs."
Contraception36, 1: 37-53 .
Ory, H. W . 1983. "Mortality associated with fertility and fertility control: 1983." FamilyPlanningPerspectives15,2: 57-63.
•Ory, H. and The Women's Health Study. 1981. "Ectopic pregnancy
and intrauterine contraceptive devices: New perspectives." Obstetricsand Gynecology57,2: 137-143.
•Oster, G.K. 1972. "Chemical reactions of the copper intrauterine device ." Fertility& Sterility 23,1: lS-23.
Pedr6n, N., M. Lozano, and R. Aznar Ramos. 1983. "Perdida sangufnea
mestrual en usuarias de dispositivos intrauterinos Cu 7 y TCu
220C." Ginecologfay Obstetriciade Mexico51,309: 25-28.
Population Information Program of the Johns Hopkins University. 1988.
"IUDs : A new look." PopulationReports,series B, no 5. Baltimore .

Rybo, G. Forthcoming. "IUD use and endometrlal bleeding." In Proceedingsof A New Lookat IUDs - AdvancingContraceptiveChoices,eds.
C.W. Bardin and D.R. Mishell, Jr . Boston:Butterworth-Heinemann.
Sagiroglu, N . 1971. "Phagocytosis of spermatozoa in the uterine cavity
of women using intrauterine devices ." InternationalJournAIof Fertility 16,1: 1-14.
Sandrnire, H.F . 1986. "Fertility after intrauterine device discontinuation ." Advancesin Contraception2: 327-335.
"Sastrawinata, S., G. Farr, S.M. Prihadi, H. Hutapea, M. Anwar, I.
Wahyudi , Sunjoto, K.P. Kemara, C.B. Champion, and M. Robbins .
1991. "A comparative clinical trial of theTCu380A, Lippes Loop D
and Multiload Cu 375 IUDs in Indonesia." Contraception44,2: 141154.
"Segal, S.J., F. Alvarez-Sanchez, C.A. Adejuwon, V. Brache de Mejia,
P. Leon, and A. Faundes . 1985. "Absence of chorionic gonadotropln In sera of women who use intrauterine devices." Fertilityand
Sterility44,2:214-218.
Shaw Jr., S.T., A.T.L. Andrade, J.P. de Souza, L.K. Macaulay, and P.J.
Rowe. 1980. "Quantitative menstrual and lntermenstrual blood loss
in women using Lippes Loop and Copper T intrauterine devices."
Contraception21,4: 343-352.
•shoham, Z., A. Lidor, E. Megory, B. Lunenfeld, J. Blankstein, and R.
Weissenberg. 1987. "The influence of different copper wires on human sperm penetration into bovine cervical mucus, in t1itro."Contraception36,3: 327-334.

Potter, J.R. 1969. "Appendix X-2: Use-effectiveness of intrauterine contraception as a problem in competing risks." In FamilyPlanning in
Taiwan: An Experiment in Social Change,eds. R. Freedman and J.
Takeshita. Princeton: Princeton University Press .

•Sinei, S.K.A., K.F. Schulz, P.R. Lamptey , D.A. Grimes, J.K.G. Mati, S.M.
Rosenthal, M.J. Rosenberg, D. Riara, P.N. Njage, V.B. Bhullar, and
H.V. Ogembo. 1990. "Preventing IUCD-related pelvic infection: The
efficacy of prophylactic doxycycline at insertion ." BritishJournalof
Obstetricsand Gynaecology97,5: 412-419.

Prema, K. 1979. "Haemoglobin levels in contraceptive users ." Indian
Journalof MedicalResearch69: 756--760.

"Sivin, I. 1984. 'The intrauterine device and uterine perforation." Obstetricsand Gynecology64,5: 744-745

Pschera, H., B. Larsson, B.A. Lindhe, and A. Kjaeldgaard. 1988. 'The
influence of copper intrauterine device on fatty acid composition
of cervical mucus lecthin." Contraception38,3: 341-348.

_ _ . 1985. "Recent studies of more effective Copper T devices ." In
Intrauterine contraception: Adt1ancesand future prospects,eds . G.I.
Zatuchni, A. Goldsmith, and J.J. Sciarra, pp . 70-78. Philadelphia:
Harper & Row.

Raltech Scientific Services, Inc. 1979. Long-termCopperT IUD\Study in
Rhesus monkeys. Commissioned by the Population Council and
Searle Laboratories. Submitted 29 March and 1 May, 1979, Madison, Wisconsin.

__

. 1989a. "An update on ectopic pregnancy and the use of intrauterine contraceptive devices" from Safety of intrauterine contraceptive devices symposium . Infectiousand MedicalDiseaselettersfor Obstetricsimd Gynecology11,3: 53-58 .

•--·

1989b. "IUDs are contraceptives, not abortifacients : A comment
on research and belief ." Studies in FamilyPlanning20,6: 355-359 .

•__

. 1991a. "Alternative estimates of ectopic pregnancy risks during contraception ." Letter to the Editor. AmericanJournalof Obstetricsand Gynecology165,6: 1,900.

•__

. 1991b. "Dose- and age-dependent ectopic pregnancy risks with
intrauterine contraception." Obstetricsand Gynecology78,2: 291-298 .

ceedingsof A New Look at IUDs - Advancing ContraceptiveChoices,

__

eds. C.W. Bardin and D.R. Mishell, Jr. Boston : ButterworthHeinemann.

. 1992. "Should collared Copper Tin tr auterine devices be replaced
before eight years? " The BritishJournalof FamilyPlanning 18: 9-11 .

__

. Forthcoming. "Intrauterine devices reduce risks of extrauterine
pregnancy." In Proceedingsof A New Lookat IUDs - AdvancingContraceptiveChoices,eds . C.W. Bardin and D.R. Mish ell, Jr. Boston :
Butterworth-Heinemann.

Rizk, M., N . Shaban, I. Medhat, Y.M. El Dien, and M . Abou Ollo. 1990.
"Electron microscopic and chemical study of the deposits formed
on the copper and inert IUCDs ." Contraception42,6: 643--653.
•Rowe, P. (World Health Organization.) 1990. Personal communication .
•Rowe, P. 1992. "Research on intrauterine devices." In Annual TechnicalReport,1991. World Health Organization: 127-134.
•Rowe, P. Forthcom ing . "Oinical performance of Copper IUDs ." In Pro-

•Roy, S., J. Casagrande, D.L. Cooper , and D.R. Mishell, Jr. 1979. "Comparison of three different models of the Copper T intrauterine contraceptive device." American Journal of Obstetrics and Gynecology
134,5: 56S-574.
Roy, S., D. Cooper, and D.R. Mishell, Jr. 1974. "Experience with three
different models of the Copper T intrauterine contraceptive device
in nulliparous women." AmericanJournalof Obstetricsand Gynecology 119,3: 414-417.

•sivin, I., F. Alvarez , J. Diaz, S. Diaz, S. El Mahgoub, E. Coutinho, V.
Brache, M.M . Diaz, A. Faundes, M. Pavez , C.E.R. Mattos, and J.
Stern. 1984. "Intrauterine contraception with copper and with
levonorgestrel : A randomized study of the TCu 380Ag and
levonorgestrel 20 mcg/ day devices ." Contraception30,5: 443-456.

25

•Sivin, I., 5. Diaz, M. Pavez, F. Alvarez, V. Brache, J. Diaz, V. Odlind,
5.-E. Olsson, and J.Stern. 1991a. "Two-year comparative trial of the
Gyne T 380 Slimline and Gyne T 380 intrauterine copper devices ."
Contraception44,5: 481-487 .
Sivin, I., 5. El Mahgoub, T. McCarthy, D.R. Mishell, Jr., D. Shoupe, F.
Alvarez, V. Brache, E. Jimenez, J. Diaz, A. Faundes, M.M. Diaz, E.
Coutinho, C.E.R. Mattos, 5. Diaz, M. Pavez, and J. Stern. 1990a.
"Long-term contraception with the Levonorgestrel 20 mcg/day
(l..Ng 20) and the Copper T 380Ag intrauterine devices : A five-year
randomized study." Contraception42,4: 361-378.
Sivin, I. and F. Schmidt. 1987. "Effectiveness of IUDs: A review ." Contraception36,1: 55-84.
*Sivin, I., M . Shaaban, V. Odlind, 5.-E. Olsson, 5. Diaz, M. Pavez, F.
Alvarez, V. Brache, and J. Diaz. 1990b. "A randomized trial of the
Gyne T and Gyne T 380 Slimline intrauterine copper devices ." Contraception42,4: 379-389 .
*Sivin, I. and J. Stern. 1979. "Long-acting, more effective Copper T IUDs:
A summary of experience, 1970-75." Studiesin FamilyPlanning10,10:
263-281.
*Sivin, I., J. Stern, E. Coutinho, C.E .R. Mattos, S. El Mahgoub, S. Diaz,
M. Pavez, F. Alvarez, V. Brache, F. Thevenin, J. Diaz, A. Faundes,
M.M. Diaz, T. McCarthy, D.R. Mishell, Jr., and D. Shoupe. 1991b.
"Prolonged intrauterine contraception: A seven-year randomized
study of the Levonorgestrel 20 mcg/day (l..Ng) and the Copper T
380 Ag IUDs ." Contraception44,5: 473-480 .
*Sivin, I., J. Stem, J. Diaz, M.M . Diaz, A. Faundes, 5. El Mahgoub, 5.
Diaz, M . Pavez, E. Coutinho, C.E.R. Mattos, T. McCarthy, D .R.
Mishell, Jr., D. Shoupe, F. Alvarez, V. Brache, and E. Jimenez. 1987.
"Two years of intrauterine contraception with levonorgestrel and
with copper: A randomized comparison of the TCu 380Ag and
levonorgestrel 20 mcg/ day devices. " Contraception35,3: 245-255.
*Sivin, I., J. Stem, S. Diaz, M. Pavez, F. Alvarez , V. Brache, D.R. Mishell,
Jr., M. Lacarra, T. McCarthy, P. Halma, P. Darney, C. Klaisle , S.-E.
Olsson, and V. Odlind. 1992 "Rates and outcomes of planned pregnancy after use of NORPLANT® capsules, NORPLANT® II rods,
or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices." AmericanJournalof Obstetricsand Gynecology
166,4: 1,20~1,213
*Sivin I. and H.J. Tatum. 1981. "Four years of experience with the TCu
380A intrauterine contraceptive device." Fertilityand Sterility 36,2:
159-163 .
*Skjeldestad, F.E. Forthcoming.

"Conception rates post removal." In

Proceedingsof A New Lookat IUDs-Advancing ContraceptiveChoices,
eds. C.W. Bardin and D.R. Mishell, Jr. Boston: ButterworthHeineman.
Skjeldestad, F. and H . Bratt. 1988. "Fertility after complicated and
noncomplicated use of IUDs: A controlled prospective study." Advancesin Contraception4: 179-184.
Stadel, B.V. and 5. Schlesselman. 1984. "Extent of surgery for pelvic
inflammatory disease in relation to duration of intrauterine device
use." Obstetricsand Gynecology63,2: 171-178.
*Stone, K.N., D.A. Grimes, and L.S. Magder. 1986. "Personal protection against sexually transmitted diseases." AmericanJournalof ObstetricsandGynecology155,1: 180-188.
*Struthers, B.J. 1985. "Pelvic inflammatory disease, intrauterine contraception, and the conduct ofepidemiologic studies ." Admnces in
Contraception1,1: 63-76.
*Sung, 5.,

26

L.-J.Qian,

and X. Uu. 1984. "Comparative

clinical expert-

ence with 3 IUDs, TCu 380Ag, TCu 220C, and Mahua Ring, in
Tianjin, People's Republic of China." Contraception29,3: 229-239.
•--

· 1985. "Two-year comparative clinical experience with three
IUDs in China . In Intrauterine Contraception
: Advancesand Future
Prospects,eds. G.I. Zatuchni, A. Goldsmith, andJ .J. Sciarra, pp. 109114. Philadelphia : Harper & Row.

Tatum, H.J., P.H. Schmidt, and A.K. Jain. 1976. "Management and outcome of pregnancies associated with the Copper T intrauterine contraceptive device ." American Journal of Obstetricsand Gynecology
126,7: 869--879.
Tatum, H .J., F.H. Schmidt, and D.M . Phillips. 1975a. "Morphological
studies of Dalkon Shield tails removed from patients." Contraception 11,4: 465-477.
Tatum, H.J., F.H. Schmidt, D. Phillips, M . McCarty, and W .M . O'Leary.
1975b. "The Dalkon Shield controversy : Structural and bacteriological studies of IUD tails." Journalof the AmericanMedicalAssociation
231,7: 711-717.
Tatum, H .J. and J.A. Zipper . 1968. "The T intrauterine contraceptive
device and recent advances in hormonal anticonceptional therapy ."
In Proceedingsof the VI. NortheastObstetricsand GynecologyCongress,
4-9 October 1968, pp. 78--85. Bahia, Brazil.
Thiery, M. and A. Kosonen . 1987. "The multisleeved Copper T model
TCu220C: Effect of long-term use on corrosion and dissolution of
copper ." Contraception35,2:163-170.
Thiery, M ., H. Van der Pas, and H. van Kets . 1985. "A decade of experience with the TCu 220C." Admnces in Contraception1,4: 313-318.
Thomas, W.O., Jr. 1977. "The Dalkon Shield, the TCu 200, and the TCu
380A in private practice." Transactionsof PacificCoastObstetricsand
Gynecological
SocietyXLIV: 78--83.
•Tianjin Family Planning Coordinate Group. 1986. "Clinical study of
three types of IUD ." ChineseJournalof Obstetricsand Gynecology21,4:
232-234.
•Tietze, C. and 5. Lewi!. 1970. "Evaluation of intrauterine devices: Ninth
progress report of the Cooperative Statistical Program ." Studies in
FamilyPlanning1,55: 1-40 .
Toivonen, J., T. Luukkainen, H. Allonen . 1991. "Protective effect of intrauterine release of levonorgestrel on pelvic infection : Three years'
comparative experience of levonorgestrel- and copper-releasing intrauterine devices." Obstetricsand Gynecology77,2: 261-264 .
•Tredway, D.R., C.U. Umezaki, D.R. Mishell, Jr ., and D.S.F. Settlage.
1975. "Effect of intrauterine devices on sperm transport in the human being: Preliminary report." AmericanJournalof Obstetricsand
Gynecology123,7: 734-735.
•Trussell, J., R.A. Hatcher, W. Cates, Jr ., F. H. Stewart, and K. Kost.
1990. "Contraceptive failure in the United States: An update ." Studiesin Family Planning21, 1: 51-54 .
•Trussell, J. and K. Kost . 1987. "Contraceptive failure in the United
States : A critical review ofthe literature ." Studies in FamilyPlanning
18,5: 237-283.
•Tsong, Y.Y. and H.A . Nash. 1991. "Effect of tarnish on copper release."
Contraception44,4: 385-392.
•van Keis, H., J. Kleinhart, M. Aster, W. Parewijck, I. Zighelboim, and
H .J. Tatum. 1991. "Clinical experience with the Gyne-T 380® postpartum intrauterine device." Fertilityand Sterility55,6: 1,144-1,149.
Vessey, M., M. Lawless, and D. Yeates . 1982. ''Efficacy of different contraceptive methods." LancetApril 10: 841--842.
Wilcox, A.J., C.R. Weinberg, F. O'Connor, D . Baird, J. Schlatterer, R.E.

Canfield, E.G. Armstrong, and B.C.Nisula. 1988. '1ncidence of early
pregnancy loss." New EnglandJournalof Medicine319,4:189-194.
•Wilcox, A.J., C.R. Weinberg, R.E. Wehmann, E.G. Armstrong, R.E.
Canfield, and B.C. Nisula. 1985. "Measuring early pregnancy loss:
Laboratory and field methods." Fertilityand Sterility 44,3: 366--374.

...

•--

•--·

· 1988. "Comparative Study of the Copper T Model TCu 380A
and the Copper T Model T 220C in Parous Women." WHO Study
79914. Geneva: World Health Organization.
1990."The TCu380A, TCu220C, Multiload 250 and Nova T IUDs
at 3, 5, and 7 years of use: Results from three randomized

multicentre trials." Contraception42,2: 141-158.

Wilson, J-C. 1989. "A prospective New Zealand study of fertility after
removal of copper intrauterine contraceptive devices for conception and because of complications: A four year-study." American
Journalof Obstetricsand Gynecology160: 391-396

Zacharias, S., E. Aguilera, J.R. Assenzo, and Juan Zanarto. 1986. "Effects of hormonal and non hormonal contraceptives on lactation and
incidence of pregnancy." Contraception33,3: 203-213.

Winikoff, B., P. Semeraro, andM. Zimmerman. 1988. Contraceptionduring Breastfeeding:A Clinician's Sourcebook.New York: The Population Council, Inc.

Zipper, J., M. Medel, A. Osorio, A. Goldschmith, and D.A. Edelman.
1976. "Long-term use effectiveness of the Cu-7-200 IUD." InternationalJournalof Gynaecologyand Obstetrics14,2: 142-144.

•World Health Organization (WHO). Research Training in Human Reproduction, Task Force on Intrauterine Devices. 1984. "PlD associated with fertility regulating agents." Contraception30,1: 1-21.

Zipper, J.A., H.J. Tatum, M. Medel, L. Pastene, and M. Rivei;:a.1971.
''.Contraception through the use of intrauterine metals. I. Copper
as an adjunct to the T device: The endouterine copper T device ."
AmericanJournalof Obstetricsand Gynecology109,5: 771-774.

•__

. 1985. "A multinational case-control study of ectopic pregnancy." ClinicalReproductionand Fertility3: 131-143.

•--·

1987. "Mechanism of Action, Safety, and Efficacy of Intrauterine Devices." Report of a WHO scientific group. Technical Report
Series 753. Geneva: World Health Organization.

Zipper, J.A., H.J. Tatum, L. Pastene, M. Medel, and M. Rivera. 1969.
"Metallic copper as an intrauterine contraception adjunct to the "T"
device." AmericanJournalof Obstetricsand Gynecology105,8: 1,2741,278.

27

GLOSSARY
Abortifacient An agent that produces abortion.

Extrauterine pregnancy (See Ectopicpregnancy.)

Barium sulfate A non-soluble powder sometimes added
during the manufacturing of IUDs so that they will show
uponx-ray.

Fallopian tubes Organs that carry the egg from the ovaries to the uterus; also called oviducts.

Blastocyst A mass of cells that become the embryoand
supporting structures. It implants in the uterine lining
seven to nine days after fertilization.
Carcinogenic Cancer causing.
Cervical canal The part of the uterus leading through
the cervix and into the vagina.
Chorionic gonadotropin A hormone produced by the
developing embryo that becomes detectable in the
mother's serum around the time of implantation. Pregnancy tests are based on the detection of human chorionic gonadotropin (hCG).
Cohort A group of individuals having factors in common, such as age, parity,education, or economic status.
Congenital anomaly A birth defect that begins during
fetal development, before the birth of the baby.

Copper ions Copper atoms carrying electrical charges.
Cytology The study of the anatomy, physiology, pathology, and chemistry of the cell.

Fertility Ability to conceive or to give birth after 12 to 24
months of trying.
Fertilization Fusion of spermatozoa and ovum to form
a zygote or pre-embryonic cell, usually in the fallopian
tubeswithin one day of ovulation.
Fetotoxic effects Toxic or causing harm to the fetus.
Glucose A simple sugar; the most common form of carbohydrate used by animals.
Gross event rates (See page 10.)
Hemoglobin A protein in red blood cells that carries oxygen.
Immunoradiometric assays A sensitive procedure for
measuring hormones (such as hCG) using antibodies and
radioisotopes.
Implantation The embedding of the fertilized egg into
the wall of the uterus.
In situ In place.

In utero In uterus.

Cytotoxic Harmful to cells.

Intrauterine In the uterus.

Degradation products Created when a chemical compound breaks down into a less complex compound.

Lactation The production of milk by the breasts after
childbirth.

Dermatitis Irritation or inflammation of the skin.

Leukocytes White blood cells.

Dysplasia Alteration in size, shape, and organization of
an organ's cells.

Lifetable (See page 10.)

Ectopic pregnancy A pregnancy occurring extrauterine,
that is, outside the uterus; most commonly in the fallo-

Monofilament A single synthetic thread or filament, tied
to the bottom of the IUD and used in detection and removal.

pian tubes.

Net event rates (See page 10.)

Embryo An organism in the early stages of development;
in human beings, this is considered to be from conception to approximately the end of the second month.

Nulliparous Never having borne children.

Endometriosis The presence of functioning endometrial
tissue outside its normal site in the lining of the uterine

cavity.
Endometritis An infection of the endometrium (the mucus membrane lining the uterus).
Epidemiology The study of incidence, risk, and exposure factors, distribution, and control of disease in a
population.
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Ova Female eggs or germ cells; plural of ovum.
Papanicolaou smear test or "Pap smear" Examination
of a smear of cells, usually from the cervix, used to detect cancer or precancerous changes in cervix that may
indicate pathology.
Parity The number of children borne by a woman.
Pathology The study of the essential nature of diseases
and the causes and development of abnormal conditions.
Pearl Index (See page 10.)

Pelvic Inflammatory Disease A general term for inflammation or infection of the ovaries, oviducts, or fallopian
tubes.
Perforation As used here, refers to holes or tears in the
walls of the uterus or cervix.

microrganisms in circulating blood.
Spermicidal Causing the death of spermatozoa.
Spermatozoa Mature male reproductive cells; sperm.
Syncope Fainting.

Phagocytosis The process of ingestion and digestion by
cells.

Teratogenic Causing malformations or serious deviations from normal development.

Polyethylene A form of plastic used in manufacture of
the T-shaped platform of the Copper T IUD.

Toxicology The scientific study of the relative safety of
substances, including those in drug and food products.

Postpartum After childbirth.

Tubal infertility Infertility-related pathology of the fal-

Radiopaque Impenetrable by x-rays and therefore visible when x-rayed.
Randomized trial A clinical study in which the volunteers are assigned a treatment, such as use of a contraceptive method, in a random way that is not determined
by the volunteers or those conducting the study.
Septic Infected or contaminated; not sterile.

lopiantubes.
Tyvek® A material widely used in sterile packaging; a
component in the Copper T packaging.
Uterine cavity The space within the uterus.
Vaginitis Inflammation of the vagina.
Wilson's disease An inherited disease characterized by
abnormal metabolism of copper.

Septicemia Systemic disease caused by the presence of
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APPENDIX

A

Statements by American and international
organizations about the IUD

sexual activity and, for properly selected women,
are a safe, effective and convenient reversible
method of contraception."

World Health Organization

Mechanism of action, safety and efficacy of intrauterine
devices
TechnicalReportSeries753, 1987
"In summary, the Scientific Group considered
the IUD to be an important method of fertility
regulation with high continuation rates and significant advantages in convenience of use. The
newer copper-releasing devices are comparable
to oral contraception in terms of safety and efficacy, and the use of IUDs in both developed and
developing countries should continue to be supported as a reliable and safe method of reversible fertility regulation."

International Planned Parenthood Federation

Statementon intrauterinedevices(IUDs)
InternationalMedicalAdvisory Panel1987,1989
"After more than two decades of widespread
use, IUDs are now used by some 60 million
women world-wide. They do not interfere with
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American College of Obstetricians and Gynecologists

TechnicalBulletin,No.164-February 1992
"The IUD is an excellent form of contraception
for selected patients . As with all methods of contraception, the benefits and risks of the method
and the needs of the patient must be considered.
Counseling is an important part of the selection
process and will identify those for whom the
IUD is a suitable contraceptive choice."

